

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in non-small cell lung cancer patients receiving immune checkpoint inhibitors: what should we expect from a meta-analysis?

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049123
Article Type:	Original research
Date Submitted by the Author:	16-Jan-2021
Complete List of Authors:	Yang, Tao; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Hao, Lizheng; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital Yang, Xinyu; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital Luo, Changyong; Beijing University of Chinese Medicine Wang, Guomi; Beijing University of Chinese Medicine Lin Cai, Caroline; London College of Chinese Medicine Qi, Shuo; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, oncology department Li, Zhong; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Department of Hematology and Oncology
Keywords:	ONCOLOGY, IMMUNOLOGY, THERAPEUTICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR)**
5
6 **in non-small cell lung cancer patients receiving immune checkpoint**
7
8 **inhibitors: what should we expect from a meta-analysis?**
9

10
11 Tao Yang^{1*} Lizheng Hao^{1*} Xinyu Yang¹ Changyong Luo² Guomi Wang³ Caroline
12
13 Lin Cai⁴ Shuo Qi⁵ Zhong Li⁶
14

15 1 Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Beijing,
16
17 China
18

19 2 Chinese Medicine College, Beijing University of Chinese Medicine, Beijing, China
20

21 3 Life Science College, Beijing University of Chinese Medicine, Beijing, China
22

23 4 London College of Chinese Medicine, London, UK
24

25 5 Department of Thyroid, Beijing University of Chinese Medicine Affiliated
26
27 Dongzhimen Hospital, Beijing, China
28

29 6 Department of Hematology and Oncology, Beijing University of Chinese Medicine
30
31 Affiliated Dongzhimen Hospital, Beijing, China
32

33 Corresponding Author: Zhong Li, PhD, Professor, Email: lizhong1711213@163.com;
34
35 Department of Hematology and Oncology, Beijing University of Chinese Medicine
36
37 Affiliated Dongzhimen Hospital, Beijing, China, 100700
38

39 *These authors contributed equally to this work.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: Derived neutrophil-to-lymphocytes ratio (dNLR) has recently been reported as a novel potential biomarker in predicting the prognosis of non-small cell lung cancer (NSCLC). However, evidence for the prognostic utility of dNLR in NSCLC patients treated with immune checkpoint inhibitors (ICIs) remains inconsistent. The objective of our meta-analysis was to assess the association of pretreatment dNLR and prognosis of NSCLC patients who were treated with ICIs.

Design: This study followed the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) guidelines (supplementary file 1).

Methods: We searched published articles from PubMed, Web of Science, EMBASE, and the Cochrane Library database. The meta-analysis of the chosen studies was conducted using STATA statistical software version 12.0.

Results: This analysis included 8 studies (2,456 cases) of the prognostic utility of dNLR in ICI therapy for NSCLC. The results indicate that elevated dNLR significantly predicted poor overall survival (OS) (hazard ratio [HR] = 1.65, 95% confidence interval [CI] 1.45–1.87; $P < 0.001$) and progression-free survival (PFS) (HR = 1.51, 95% CI 1.24–1.85; $P < 0.001$). Subgroup analyses of OS-related studies indicated that there were similar results in stratifications by ethnicity, sample size, type of HR, and dNLR cut-off value. As for PFS-related studies, subgroup analyses showed no significant difference in Asian populations. Publication biases were not detected using Begg's test and Egger's linear regression test.

Conclusions: This meta-analysis indicated that elevated pretreatment dNLR may be a negative prognostic predictor for NSCLC patients treated with ICIs. More large-sample and higher quality studies are warranted to support our findings.

PROSPERO registration number: CRD42021214034

Keywords: derived neutrophil-to-lymphocyte ratio, immune checkpoint inhibitors, non-small cell lung cancer, meta-analysis

Strengths and limitations of this study

► This is the first study to evaluate the prognostic value of pretreatment dNLR in

1
2
3
4 NSCLC patients who treated with ICIs.

- 5
6 ▶ This meta-analysis may provide novel prognostic guidance for NSCLC patients
7 treated with ICIs.
8
9 ▶ All the studies included in this meta-analysis were retrospective cohort studies, and
10 the number of eligible studies was < 10, so there may be some retrospective bias
11 and publication bias.
12
13
14
15
16

17 **Introduction**

18
19 Global cancer statistics have shown that there are 1.24 million new cases and 1.09
20 million deaths from lung cancer each year.¹ Non-small cell lung cancer (NSCLC)
21 accounts for about 85% of primary lung cancers and includes 3 main pathological types:
22 squamous cell carcinoma, adenocarcinoma, and large cell lung cancer.² The treatment
23 strategy for NSCLC depends on the stage of the cancer. Early stage patients should be
24 treated with surgical resection, while advanced stage patients are mainly treated with
25 systematic therapy. The five-year survival rates for NSCLC range from 14% to 49% for
26 stage I-IIIa patients, and are less than 5% for stage IIIB-IV disease.³ In the past ten
27 years, the application of immune checkpoint inhibitors (ICIs) in the treatment of
28 NSCLC has improved the therapeutic landscape for this intractable disease. Some
29 patients with advanced NSCLC have shown overall survival (OS) or progression-free
30 survival (PFS) benefits from ICI treatment after chemoradiotherapy.^{4 5} Despite
31 significant clinical improvements, not all ICI treatments are effective in NSCLC
32 patients. Some valuable biomarkers that predict ICI response, such as programmed cell
33 death-ligand 1 (PD-L1), tumour mutational burden, and tumour-infiltrating
34 lymphocytes which could indicate the status of the tumour immune microenvironment
35 have led to more effective application of ICIs.⁶ However, most of these biomarkers are
36 detected in an invasive manner, which depends heavily on sufficient tumour tissue.
37 Thus, there is an urgent need to explore and evaluate better biomarkers for selecting
38 patients suitable for ICI treatment.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57
58 Inflammation processes have been proven to be mechanisms of immune resistance in
59
60

1
2
3
4 cancer patients which can promote tumour growth and invasion and activate
5 carcinogenic signalling pathways.⁷ In clinical practice, peripheral serum indicators are
6 used to evaluate systemic inflammation, and some of them are associated with
7 prognosis and therapeutic response of patients with cancer.^{8 9} The common
8 haematological inflammatory indicators include white blood cells (WBC), lymphocytes,
9 and C-reactive protein (CRP). Derived neutrophil-to-lymphocyte ratio (dNLR) is a
10 novel potential biomarker for systemic inflammation, which can be calculated by
11 absolute value of neutrophils and value of leucocyte count.¹⁰ DNLr has been used to
12 assess response to immunotherapy in various cancers, including NSCLC.¹¹⁻¹³ Recent
13 studies showed the predictive utility of pretreatment dNLR in urological cancer and
14 breast cancer.^{14 15} However, evidence of the association between the prognosis of
15 NSCLC and dNLR remains mixed. Therefore, the objective of our study was to explore
16 the relationship between pretreatment dNLR and survival in NSCLC patients treated
17 with ICIs.
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Methods**

32 **Patient and public involvement**

33 It was not appropriate or possible to involve patients or the public in the design, conduct,
34 reporting, or dissemination plans of our research.
35
36
37
38

39 **Search strategy and study inclusion**

40 Our meta-analysis was conducted to explore the association between dNLR and
41 prognosis of NSCLC patients treated with ICIs. We conducted a search of four
42 electronic journal databases: PubMed, EMBASE, Web of Science, and the Cochrane
43 Library. The search consisted of three parts: 1) the subject words (Emtree in EMBASE
44 and MeSH in other databases) and free words of NSCLC were searched respectively,
45 2) the abbreviations and specific names of ICIs were searched, 3) dNLR and its full
46 name were also searched. The last search was updated on 16 October 2020.
47 (supplementary file 2)
48
49
50
51
52
53
54
55

56 The inclusion criteria were as follows: 1) human subjects receiving ICIs therapy and
57 who had been diagnosed with NSCLC; 2) the baseline values of dNLR were obtained;
58
59
60

1
2
3
4 3) the objective of the study was to investigate the relationships between dNLR and OS
5 or PFS in NSCLC; 4) hazard ratio (HR) and 95% confidence interval (CI) were
6 displayed in the original article or could be extracted from Kaplan-Meier curves.
7

8
9 The exclusion criteria were as follows: (1) studies including subjects with other diseases;
10 (2) case reports, reviews, meta-analyses, conference abstracts, and letters; (3) duplicate
11 publications; (4) we were unable to acquire the full text or data from the text.
12
13

14 15 **Quality assessment**

16
17 We evaluated the quality of the included studies using the Newcastle-Ottawa Scale
18 (NOS),¹⁶ which assesses three aspects of the studies: selection, comparability, and
19 outcome. Each study could be given a maximum of 9 stars. A higher number of stars
20 indicated better study quality.
21
22

23 24 **Data extraction**

25
26 Two investigators independently extracted data. Any disagreement was settled by
27 discussion until agreement was reached or by consulting a third investigator. Data
28 extracted were author, year of publication, study districts, age, sample size, type of ICIs,
29 median follow-up time, cut-off value of dNLR, and clinical stage. As for quantitative
30 data, HRs with 95% CI of OS and PFS were also acquired from the included studies.
31
32

33 34 **Statistical analysis**

35
36 To evaluate the association between pretreatment dNLR and survival outcomes of the
37 NSCLC patients treated with ICIs, HRs with 95% CI were gathered to give the effective
38 value. We assessed the heterogeneity of the eligible studies by using Cochran's Q test
39 and I^2 statistics. $I^2 > 50\%$ and $P < 0.05$ in the Cochran's Q test were considered to
40 indicate significant heterogeneity, and the random effects model was applied to
41 calculate the pooled HRs. If heterogeneity was not significant, the fixed effects model
42 was utilised. Subgroup analysis was conducted to assess heterogeneity among the
43 results of different studies and explore the stability of results in different stratifications.
44
45 Publication bias of studies was assessed by Begg's test and Egger's test. All P-values
46 were two-sided, and $P < 0.05$ was considered statistically significant. STATA statistical
47 software version 12.0 was used for all statistical analysis in this study.
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Study characteristics

A total of 193 articles were retrieved using the initial search strategies. After multiple screening processes, 8 studies with a total of 2,456 patients, published between 2018 and 2020, were finally included in our meta-analysis. The flow chart of study inclusion is shown in Figure 1. Among all studies, participants in 2 studies were Asian^{17 18} and in the other 6 were European or American.^{13 19-23} HRs and 95% CIs were reported exactly in 7 studies,¹⁷⁻²³ while the remaining study¹³ reported only HR and P-value; we then estimated 95% CI for that study based on HR and P value.²⁴ This study¹³ computed HRs using univariable analysis and the other 7 studies applied multivariable analysis.¹⁷⁻²³ Four of the study cohorts^{13 19-21} enrolled <200 patients and 4 cohorts^{17 18 22 23} had >200 patients. The cut-off values of NLR applied in the studies were not consistent, ranging from 2.2 to 3.0. Six studies involved stage III-IV/IIIb-IV cancer, and 2 studies did not clearly report stage.^{13 17} All studies investigated the associations of dNLR and OS, and 7 studies reported the associations of dNLR and PFS. The attributes of the eligible studies are shown in Table 1, and the NOS score of included studies is shown in Table 2.

Figure 1. Flow chart of the eligible studies

Table 1. Main characteristics of all the eligible studies in the meta-analysis

Author	Year	Country	Ethnicity	Age (median and range)	Sample size	ICIs	Cut off value	Stage	Variable	Median follow-up time (months)
Russo A ¹³	2018	Italy	European	69(47-78)	28	Nivo	3	NA	U	17
Mezquita L	2018	France	European	NA	305	NA	3	IV	M	12
Prelaj A ¹⁹	2019	Italy	European	67(31-86)	154	Nivo/Pembro	2.2	IIIb-IV	M	NA
Kazandjian D ²³	2019	USA	America	NA	1368	NA	3	IV	M	NA
Seban R ²⁰	2020	France	European	65(37-86)	63	Pembro	3	IIIb-IV	M	13.4
Seban R ²¹	2020	France	European	61.9(34.2-84.8)	109	Nivo/Pembro/Atezo	3	III-IV	M	11.6
Yuan S ¹⁸	2020	China	Asian	66(57-69)	203	Pembro/Nivo/Tori/Sinti/Cam/Tis	2.35	IIIb-IV	M	NA
Takada K ¹⁷	2020	Japan	Asian	66(31-88)	226	Nivo/Pembro	2.79	NA	M	13.8

NA: not available; Nivo: nivolumab; Pembro: pembrolizumab; Atezo: atezolizumab; Crizo: crizotinib; Sinti: sintilizumab; Tori: toripalimab; Cam: camrelizumab; Tis: tislelizumab; U: univariable; M: multivariable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 2. Quality assessment of included studies

Studies	Representativeness of population	Non-respondents	Ascertainment of the exposure	Outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Enough follow-up period	Adequacy of follow-up of cohorts	Total stars
Russo A 2018	☆	☆	☆	☆	☆-	☆	☆	☆	8
Mezquita L 2018	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Prelaj A 2019	☆	☆	☆	☆	☆☆	☆	-	☆	8
Kazandjian D 2019	☆	☆	☆	☆	☆☆	☆	-	☆	8
Seban R 2020	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Seban R 2020	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Yuan S 2020	☆	☆	☆	☆	☆☆	☆	-	☆	8
Takada K 2020	☆	☆	☆	☆	☆☆	☆	☆	☆	9

☆represents the score of the study in this item. -, no star in this item.

Association between pretreatment dNLR and OS in NSCLC

Eight studies with 2,456 patients were finally included in our analysis of the association between pretreatment dNLR and OS. A fixed effects model was applied due to relatively satisfactory homogeneity ($I^2=20.6\%$, $P = 0.266$). Our pooled result indicated that elevated pretreatment dNLR predicted a worse outcome for OS (HR = 1.65, 95% CI 1.45–1.87; $P < 0.001$) (Figure 2) compared with those with low pretreatment dNLR. In subgroup analyses by ethnicity, the pooled HR was 1.53 (95% CI 1.18–1.98; $P = 0.001$) for Asian patients and 1.69 (95% CI 1.46–1.94; $P < 0.001$) for European or American patients. Stratification by sample size found that dNLR was a negative predictor for OS in both the large sample size group (HR: 1.62, 95% CI 1.42–1.85; $P < 0.001$) and the small sample size group (HR: 1.90, 95% CI 1.28–2.82; $P < 0.001$). In subgroup analyses by cut-off value ≥ 3 and cut-off value < 3 , the data showed that the pooled HR was 1.60 (95% CI 1.41–1.82, $P < 0.001$) for cut-off value ≥ 3 and 2.28 (95%CI 1.54–3.99, $P < 0.001$) for cut-off value < 3 . Subgroup analysis was conducted using univariable and multivariable analysis (Table 3).

Figure 2. Forest plot of the association between pretreatment dNLR and OS

Association between pretreatment dNLR and PFS in NSCLC

Seven studies including 2,151 patients were finally selected for analysis of the association between pretreatment dNLR and PFS. A random effects model was adopted due to $I^2=50.5\%$ and $P=0.059$. The results demonstrated that high pretreatment dNLR was significantly associated with poorer PFS (HR = 1.51, 95% CI 1.24–1.85; $P < 0.001$) (Figure 3) compared with low pretreatment dNLR. Subgroup analysis was performed by ethnicity; the results showed that dNLR was a negative predictor for NSCLC both in Asian (HR = 1.57, 95% CI 0.97–2.54; $P = 0.068$) and European or American patients (HR = 1.45, 95% CI 1.15–1.84; $P = 0.002$). In the small sample size group, the pooled HR was 1.80 (95% CI 1.28–2.53; $P = 0.001$), and in the large sample size group the HR was 1.35 (95% CI 1.20–1.53; $P < 0.001$). Subgroup analyses by cut-off value of dNLR

1
2
3
4 showed that the pooled HR was 1.47 (95% CI 1.15-1.88, $P < 0.001$) for cutoff value =
5
6 3 and 1.75 (95% CI 1.19-2.56, $P = 0.004$) for cut-off value < 3 . Furthermore, subgroup
7
8 analysis was conducted using univariable and multivariable analysis, and the results
9
10 also illustrated the interrelation between baseline dNLR and PFS (Table 3).
11
12

13
14 Figure 3. Forest plot of the association between pretreatment dNLR and PFS
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 3. Summary of the subgroup analysis results in studies with dNLR

Variables	OS					PFS				
	Number of studies	Pooled HR (95% CI)	P	I2	Ph	Number of studies	Pooled HR (95% CI)	P	I2	Ph
Ethnicity										
Asian	2	1.53 (1.18,1.98)	0.001	0.00%	0.56	2	1.57 (0.97,2.54)	0.068	85.30%	0.009
European/American	6	1.69 (1.46,1.94)	0	37.90%	0.154	5	1.45 (1.15,1.84)	0.002	19.10%	0.293
Sample size										
≤200	4	1.90 (1.28,2.82)	0	60.50%	0.055	4	1.80 (1.28,2.53)	0.001	0.00%	0.669
> 200	4	1.62 (1.42,1.85)	0	0.00%	0.883	3	1.35 (1.20,1.53)	0.007	75.40%	0.017
Type of analysis										
Univariable	1	-	-	-	-	1	-	-	-	-
Multivariable	7	1.66 (1.46,1.88)	0	26.60%	0.226	6	1.40 (1.25,1.57)	0	57.40%	0.038
dNLR cut-off value										
<3	3	2.28 (1.54,3.99)	0	48.60%	0.143	3	1.75 (1.19,2.56)	0.004	0.00%	0.487
=3	5	1.60 (1.41,1.82)	0	0.00%	0.751	4	1.47 (1.15,1.88)	0.002	67.40%	0.027

Publication bias

We conducted Begg's and Egger's linear regression test to assess publication bias. OS publication bias was not discovered in studies with dNLR ($Pr>|z|=0.902$ for Begg's test and $P>|t|=0.623$ for Egger's test); publication bias was also not detected for PFS ($Pr>|z|=1.0$ and $P>|t|=0.198$, respectively). The plots of Begg's test and Egger's test are shown in Figure 4.

Figure 4. Funnel plot for analysis of publication bias. (A) Funnel plot established using Begg's test for studies with OS; (B) funnel plot utilising Egger's test for studies with OS. (C) Funnel plot established utilising Begg's test for studies with PFS; (D) funnel plot utilising Egger's test for studies with PFS.

Discussion

This meta-analysis evaluated the results of 2,456 NSCLC patients in 8 studies. The results showed that high level dNLR was a significant predictor of worse OS (HR = 1.65, 95% CI 1.45–1.87; $P < 0.001$) and PFS (HR = 1.51, 95% CI 1.24–1.85; $P < 0.001$) of NSCLC patients treated with ICIs. Subgroup analyses of OS-related studies indicated similar results in stratifications by ethnicity, sample size, type of HR, and dNLR cut-off value. In PFS-related studies, subgroup analyses showed that there was no significant difference in the Asian sample group. We conclude that pretreatment dNLR may be an important biomarker of the prognosis of NSCLC patients treated with ICIs. Inflammation tends to lead to the development of cancer and stimulates all stages of tumourigenesis through multiple mechanisms.²⁵ Induction of inflammation can bring increased mutagenesis, leading to collection of mutations in normal tissue that can further cause tumour formation.^{26 27} Unlike in earlier stages of oncogenesis, cancer-related inflammation plays a crucial role in regulation of metastasis and leads to worse mortality.²⁸ Additionally, the inflammation process has been suggested as a reason for immune resistance in cancer patients. The cellular effectors of inflammation are significant elements of the tumour microenvironment that break down adaptive immune

1
2
3
4 responses and impede responses to anti-tumour agents.²⁹ Moreover, a peripheral pro-
5
6 inflammatory condition has been linked to poor prognosis in patients with cancer⁷.
7
8 Many routine blood indices including WBC, CRP, absolute neutrophil count, and
9
10 lactate dehydrogenase level have been evaluated as potential inflammatory biomarkers,
11
12 which are associated with worse survival in various types of cancer.³⁰⁻³² Novel
13
14 biomarkers such as NLR, lymphocyte-monocyte ratio (LMR), and lymphocyte-platelet
15
16 ratio (PLR) have also been used to assess inflammatory status in several cancer types,
17
18 including NSCLCs.³³⁻³⁵ In particular, NLR is a well-studied prognostic predictor in
19
20 NSCLC patients, and some meta-analyses have confirmed the predictive value of NLR
21
22 in patients with NSCLC.^{36 37}

23
24 Recent studies indicated that dNLR is a novel serum marker of inflammatory in NSCLC
25
26 patients treated with ICIs.^{13 38} Although some studies have suggested relationships
27
28 between NLR and survival and therapeutic outcomes in NSCLC patients treated with
29
30 anti-PD-1 inhibitors,^{8 39 40} dNLR may be more strongly linked because it includes
31
32 monocytes and other granulocytes. Immature or poorly differentiated neutrophils can
33
34 be released in a pro-inflammatory environment, which increases neutrophil generation
35
36 rapidly. dNLR seems to reflect this negative inflammation more comprehensively. Our
37
38 study demonstrated that dNLR may be a valuable prognostic serum biomarker for
39
40 clinicians' decision making in NSCLC ICIs treatment. Future studies should pay more
41
42 attentions to the prognostic effect of dNLR on the NSCLC patients with ICIs. A larger
43
44 sample study is needed to verify our results.

45
46 Most studies have chosen a dNLR cut-off value of 3 to distinguish the prognosis of
47
48 NSCLC patients treated with ICIs. It is also probably necessary to use receiver
49
50 operating characteristic (ROC) curves to determine the best cut-off value of dNLR
51
52 based on large sample data, so that dNLR can be better applied to clinical practice.

53
54 Several limitations of our meta-analysis require careful consideration. First, the
55
56 eligible studies were all retrospective, so retrospective biases may influence the
57
58 accuracy of results. Second, although neither Begg's test nor Egger's test showed
59
60 publication bias in this study, the effectiveness of the two tests was low when the

1
2
3
4 number of meta-analyses was < 10. In addition, our study mainly searched English-
5 language databases. Hence, publication bias should also be considered.
6

7
8 In conclusion, this meta-analysis revealed that elevated pretreatment dNLR may be a
9 negative prognostic index for NSCLC patients treated with ICIs. Future well-designed
10 and large-scale studies are needed to validate the result.
11
12

13 **Acknowledgements**

14
15 None.
16

17 **Author contributions**

18
19 ZL and SQ put forward the idea of research. The search strategy was developed and
20 conducted by TY, LH, and XY. LH and XY independently screened the titles and
21 abstracts of all included studies. Data extraction was performed by LH, XY, CL, and
22 GW. TY and LH conducted the meta-analysis. Manuscript was written by TY and CLC.
23
24
25
26

27 **Funding**

28
29 None.
30

31 **Compliance with ethical standards**

32 **Conflict of interest**

33
34 The authors declare that they have no competing interests.
35

36 **Ethical approval**

37
38 Not applicable.
39

40 **Patient consent for publication**

41
42 Not applicable.
43

44 **Data availability**

45
46 No additional data available.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians* 2018;68(6):394-424. doi: 10.3322/caac.21492
2. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. *Mayo Clinic proceedings* 2019;94(8):1623-40. doi: 10.1016/j.mayocp.2019.01.013 [published Online First: 2019/08/06]
3. Ko EC, Raben D, Formenti SC. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. *Clin Cancer Res* 2018;24(23):5792-806. doi: 10.1158/1078-0432.Ccr-17-3620 [published Online First: 2018/06/28]
4. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. 2017;377(20):1919.
5. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *N Engl J Med* 2018;379(24):2342-50. doi: 10.1056/NEJMoa1809697 [published Online First: 2018/10/04]
6. Bodor JN, Bumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). *Cancer* 2020;126(2):260-70. doi: 10.1002/cncr.32468 [published Online First: 2019/11/07]
7. Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *JAMA oncology* 2018;4(3):351-57. doi: 10.1001/jamaoncol.2017.4771 [published Online First: 2018/01/13]

- 1
2
3
4 8. Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a
5
6 marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung
7
8 cancer. *Lung Cancer* 2017;106:1-7. doi: 10.1016/j.lungcan.2017.01.013 [published
9
10 Online First: 2017/03/14]
11
12
13
14 9. Pine JK, Morris E, Hutchins GG, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal
15
16 cancer: the relationship to patient survival, tumour biology and local lymphocytic
17
18 response to tumour. *Br J Cancer* 2015;113(2):204-11. doi: 10.1038/bjc.2015.87
19
20 [published Online First: 2015/07/01]
21
22
23
24 10. Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio
25
26 predicts survival in patients with cancer. *Br J Cancer* 2012;107(4):695-9. doi:
27
28 10.1038/bjc.2012.292 [published Online First: 2012/07/26]
29
30
31
32 11. Afzal MZ, Sarwar T, Shirai K. Prognostic Significance of Hematological Indices in Malignant
33
34 Melanoma Treated With Immune Checkpoint Inhibitors. *J Immunother* 2019;42(7):251-
35
36 64. doi: 10.1097/cji.0000000000000272 [published Online First: 2019/05/31]
37
38
39
40 12. Bruixola G, Caballero J, Papaccio F, et al. Prognostic Nutritional Index as an independent
41
42 prognostic factor in locoregionally advanced squamous cell head and neck cancer.
43
44 *ESMO open* 2018;3(6):e000425. doi: 10.1136/esmoopen-2018-000425 [published
45
46 Online First: 2018/11/15]
47
48
49
50 13. Russo A, Franchina T, Ricciardi GRR, et al. Baseline neutrophilia, derived neutrophil-to-
51
52 lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small
53
54 cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. *Journal of cellular*
55
56 *physiology* 2018;233(10):6337-43. doi: 10.1002/jcp.26609
57
58
59
60

- 1
2
3
4 14. Su S, Liu L, Li C, et al. Prognostic role of pretreatment derived neutrophil to lymphocyte
5
6 ratio in urological cancers: A systematic review and meta-analysis. *International journal*
7
8
9
10
11
12 [published Online First: 2019/11/11]
13
14 15. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and
15
16 derived NLR are associated with poor prognosis in patients with breast cancer: A meta-
17
18 analysis. *Medicine* 2018;97(49):e13340. doi: 10.1097/md.00000000000013340
19
20
21
22 [published Online First: 2018/12/14]
23
24 16. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies
25
26 in Meta-Analyses. Symposium on Systematic Reviews: Beyond the Basics; 2014.
27
28
29 17. Takada K, Takamori S, Yoneshima Y, et al. Serum markers associated with treatment
30
31 response and survival in non-small cell lung cancer patients treated with anti-PD-1
32
33 therapy. *Lung Cancer* 2020;145:18-26. doi: 10.1016/j.lungcan.2020.04.034
34
35
36
37 18. Yuan S, Xia Y, Shen L, et al. Development of nomograms to predict therapeutic response
38
39 and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.
40
41
42
43
44
45
46
47 19. Prelaj A, Rebuzzi SE, Pizzutilo P, et al. EPSILoN: A Prognostic Score Using Clinical and
48
49 Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With
50
51 Immunotherapy. *Clinical lung cancer* 2020;21(4):365-77.e5. doi:
52
53
54
55 10.1016/j.clcc.2019.11.017 [published Online First: 2020/04/05]
56
57 20. Seban RD, Assié JB, Giroux-Ieprieur E, et al. Association of the metabolic score using
58
59 baseline FDG-PET/CT and DNLR with immunotherapy outcomes in advanced NSCLC
60

- 1
2
3
4 patients treated with first - line pembrolizumab. *Cancers* 2020;12(8):1-14. doi:
5
6 10.3390/cancers12082234
7
8
9 21. Seban RD, Mezquita L, Berenbaum A, et al. Baseline metabolic tumor burden on FDG
10
11 PET/CT scans predicts outcome in advanced NSCLC patients treated with immune
12
13 checkpoint inhibitors. *European journal of nuclear medicine and molecular imaging*
14
15 2020;47(5):1147-57. doi: 10.1007/s00259-019-04615-x
16
17
18
19 22. Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index
20
21 With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small
22
23 Cell Lung Cancer. *JAMA oncology* 2018;4(3):351-57. doi:
24
25 10.1001/jamaoncol.2017.4771
26
27
28
29 23. Kazandjian D, Gong Y, Keegan P, et al. Prognostic Value of the Lung Immune Prognostic
30
31 Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer. *JAMA oncology*
32
33 2019;5(10):1481-85. doi: 10.1001/jamaoncol.2019.1747
34
35
36
37 24. Altman DG, Bland JM. How to obtain the confidence interval from a P value. *BMJ*
38
39 2011;343:d2090. doi: 10.1136/bmj.d2090 [published Online First: 2011/08/10]
40
41
42
43 25. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and
44
45 Consequences. *Immunity* 2019;51(1):27-41. doi: 10.1016/j.immuni.2019.06.025
46
47 [published Online First: 2019/07/18]
48
49
50 26. Canli Ö, Nicolas AM, Gupta J, et al. Myeloid Cell-Derived Reactive Oxygen Species Induce
51
52 Epithelial Mutagenesis. *Cancer cell* 2017;32(6):869-83.e5. doi:
53
54 10.1016/j.ccell.2017.11.004 [published Online First: 2017/12/13]
55
56
57
58 27. Robles AI, Traverso G, Zhang M, et al. Whole-Exome Sequencing Analyses of Inflammatory
59
60


- 1
2
3
4 Bowel Disease-Associated Colorectal Cancers. *Gastroenterology* 2016;150(4):931-43.
5
6 doi: 10.1053/j.gastro.2015.12.036 [published Online First: 2016/01/15]
7
8
9 28. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis:
10
11 a study of incident cancers during randomised controlled trials. *Lancet*
12
13 2012;379(9826):1591-601. doi: 10.1016/s0140-6736(12)60209-8 [published Online
14
15 2012/03/24]
16
17
18 29. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. *Nature*
19
20 2008;454(7203):436-44. doi: 10.1038/nature07205 [published Online First: 2008/07/25]
21
22
23 30. Soyano AE, Dholaria B, Marin-Acevedo JA, et al. Peripheral blood biomarkers correlate
24
25 with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1
26
27 antibodies. *J Immunother Cancer* 2018;6(1):129. doi: 10.1186/s40425-018-0447-2
28
29 [published Online First: 2018/11/25]
30
31
32 31. Wang H, Wang MS, Zhou YH, et al. Prognostic Values of LDH and CRP in Cervical Cancer.
33
34 *OncoTargets and therapy* 2020;13:1255-63. doi: 10.2147/ott.S235027 [published
35
36 Online First: 2020/02/28]
37
38
39 32. Yoon CI, Park S, Cha YJ, et al. Associations between absolute neutrophil count and
40
41 lymphocyte-predominant breast cancer. *Breast (Edinburgh, Scotland)* 2020;50:141-48.
42
43 doi: 10.1016/j.breast.2019.09.013 [published Online First: 2019/10/15]
44
45
46 33. Xiao X, Wang S, Long G. C-reactive protein is a significant predictor of improved survival
47
48 in patients with advanced non-small cell lung cancer. *Medicine* 2019;98(26):e16238.
49
50 doi: 10.1097/md.00000000000016238 [published Online First: 2019/07/03]
51
52
53 34. Machado D, Marques C, Dias M, et al. Inflammatory prognostic biomarkers in advanced
54
55
56
57
58
59
60

- 1
2
3
4 non-small cell lung cancer. *Pulmonology* 2019;25(3):181-83. doi:
5
6 10.1016/j.pulmoe.2019.02.007 [published Online First: 2019/04/03]
7
8
9 35. Cedrés S, Torrejon D, Martínez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator
10
11 of poor prognosis in stage IV non-small cell lung cancer. *Clin Transl Oncol*
12
13 2012;14(11):864-9. doi: 10.1007/s12094-012-0872-5 [published Online First:
14
15 2012/08/03]
16
17
18
19 36. Wang Z, Zhan P, Lv Y, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio
20
21 in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis.
22
23 *Translational lung cancer research* 2019;8(3):214-26. doi: 10.21037/tlcr.2019.06.10
24
25 [published Online First: 2019/08/02]
26
27
28
29 37. Benedict SD, Anne LJ, Dennis SJO, et al. Prognostic utility of baseline neutrophil-to-
30
31 lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-
32
33 analysis. 2018;Volume 11:955-65.
34
35
36
37 38. Blanc-Durand F, Auclin E, Planchard D, et al. Association of lung immune prognostic index
38
39 (LIPI) with survival of first line immune checkpoint inhibitors single agent or in
40
41 combination with chemotherapy in untreated advanced NSCLC patients. *Annals of*
42
43 *Oncology* 2019;30:xi5. doi: 10.1093/annonc/mdz447.015
44
45
46
47
48 39. Park W, Lopes G. Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker
49
50 in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer. *Clinical lung cancer*
51
52 2019;20(3):143-47. doi: 10.1016/j.clcc.2018.12.003 [published Online First: 2019/01/27]
53
54
55
56 40. Jiang T, Bai Y, Zhou F, et al. Clinical value of neutrophil-to-lymphocyte ratio in patients with
57
58 non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. *Lung Cancer*
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2019;130:76-83. doi: 10.1016/j.lungcan.2019.02.009 [published Online First:
2019/03/20]


For peer review only



Flow chart of the eligible studies


181x245mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Forest plot of the association between pretreatment dNLR and OS

456x326mm (72 x 72 DPI)



Forest plot of the association between pretreatment dNLR and PFS

464x327mm (72 x 72 DPI)



Funnel plot for analysis of publication bias. (A) Funnel plot established using Begg's test for studies with OS; (B) funnel plot utilising Egger's test for studies with OS. (C) Funnel plot established utilising Begg's test for studies with PFS; (D) funnel plot utilising Egger's test for studies with PFS.



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	5



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	5
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	5
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6-7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9-10
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9-10
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9-10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	11
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	14

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Supplementary Table 1 Search strategies for PubMed, Embase, Cochrane Library and Web of science

Database	Keywords
PubMed	
#1	"Carcinoma, Non-Small-Cell Lung"[Mesh]
#2	(Carcinoma, Non Small Cell Lung[Title/Abstract]) OR (Carcinomas, Non-Small-Cell Lung[Title/Abstract]) OR (Lung Carcinoma, Non-Small-Cell[Title/Abstract]) OR (Lung Carcinomas, Non-Small-Cell[Title/Abstract]) OR (Non-Small-Cell Lung Carcinomas[Title/Abstract]) OR (Nonsmall Cell Lung Cancer[Title/Abstract]) OR (Non-Small-Cell Lung Carcinoma[Title/Abstract]) OR (Non Small Cell Lung Carcinoma[Title/Abstract]) OR (Carcinoma, Non-Small Cell Lung[Title/Abstract]) OR (Non-Small Cell Lung Cancer[Title/Abstract])
#3	#1 OR #2
#4	(checkpoint*[Title/Abstract]) OR ("checkpoint inhibitor"[Title/Abstract]) OR (CTLA-4[Title/Abstract]) OR (PD-1[Title/Abstract]) OR (PD-L1[Title/Abstract]) OR (ipilimumab[Title/Abstract]) OR (atezolizumab[Title/Abstract]) OR (durvalumab[Title/Abstract]) OR (pembrolizumab[Title/Abstract]) OR (nivolumab[Title/Abstract]) OR (avelumab[Title/Abstract]) OR (tremelimumab[Title/Abstract])
#5	(derived neutrophil-lymphocyte ratio[Title/Abstract]) OR (dNLR[Title/Abstract]) OR (derived neutrophil lymphocyte ratio[Title/Abstract]) OR (derived neutrophil to lymphocyte ratio[Title/Abstract])
#6	#3 AND #4 AND #5
Embase	
#1	'non small cell lung cancer'/exp
#2	'carcinoma, non small cell lung':ab,ti OR 'carcinomas, non-small-cell lung':ab,ti OR 'lung carcinoma, non-small-cell':ab,ti OR 'lung carcinomas, non-small-cell':ab,ti OR 'non-small-cell lung carcinomas ':ab,ti OR 'non small cell lung cancer':ab,ti OR 'non-small-cell lung carcinoma':ab,ti OR 'non small cell lung carcinoma ':ab,ti OR 'carcinoma, non-small cell lung':ab,ti OR 'non-small cell lung cancer':ab,ti
#3	#1 OR #2
#4	'checkpoint*':ab,ti OR 'checkpoint inhibitor':ab,ti OR 'ctla-4':ab,ti OR 'pd-1':ab,ti OR 'pd-11':ab,ti OR 'ipilimumab':ab,ti OR 'atezolizumab':ab,ti OR 'durvalumab':ab,ti OR 'pembrolizumab':ab,ti OR 'nivolumab':ab,ti OR 'avelumab':ab,ti OR 'tremelimumab':ab,ti
#5	'derived neutrophil-lymphocyte ratio':ab,ti OR 'dnlr':ab,ti OR 'derived neutrophil lymphocyte ratio':ab,ti OR 'derived neutrophil to lymphocyte ratio':ab,ti
#6	#3 AND #4 AND #5
Cochrane Library	
#1	MeSH: Carcinoma, Non-Small-Cell Lung

#2	(Carcinoma, Non Small Cell Lung):ti,ab,kw OR (Carcinomas, Non-Small-Cell Lung):ti,ab,kw OR (Lung Carcinoma, Non-Small-Cell):ti,ab,kw OR (Lung Carcinomas, Non-Small-Cell):ti,ab,kw OR (Non-Small-Cell Lung Carcinomas):ti,ab,kw OR (Non small Cell Lung Cancer):ti,ab,kw OR (Non-Small-Cell Lung Carcinoma):ti,ab,kw OR (Non Small Cell Lung Carcinoma):ti,ab,kw OR (Carcinoma, Non-Small Cell Lung):ti,ab,kw OR (Non-Small Cell Lung Cancer):ti,ab,kw
#3	#1 OR #2
#4	(checkpoint*):ti,ab,kw OR (checkpoint inhibitor):ti,ab,kw OR (CTLA-4):ti,ab,kw OR (PD-1):ti,ab,kw OR (PD-L1):ti,ab,kw OR (ipilimumab):ti,ab,kw OR (atezolizumab):ti,ab,kw OR (durvalumab):ti,ab,kw OR (pembrolizumab):ti,ab,kw OR (nivolumab):ti,ab,kw OR (avelumab):ti,ab,kw OR (tremelimumab):ti,ab,kw
#5	(derived neutrophil-lymphocyte ratio):ti,ab,kw OR (dNLR):ti,ab,kw OR (derived neutrophil lymphocyte ratio):ti,ab,kw OR (derived neutrophil to lymphocyte ratio):ti,ab,kw
#6	#3 AND #4 AND #5
Web of science	
#1	TS=(Carcinoma, Non-Small-Cell Lung OR Carcinoma, Non Small Cell Lung OR Carcinomas, Non-Small-Cell Lung OR Lung Carcinoma, Non-Small-Cell OR Lung Carcinomas, Non-Small-Cell OR Non-Small-Cell Lung Carcinomas OR Non small Cell Lung Cancer OR Non-Small-Cell Lung Carcinoma OR Non Small Cell Lung Carcinoma OR Carcinoma, Non-Small Cell Lung OR Non-Small Cell Lung Cancer)
#2	TS=(checkpoint* OR checkpoint inhibitor OR CTLA-4 OR PD-1 OR PD-L1 OR ipilimumab OR atezolizumab OR durvalumab OR pembrolizumab OR nivolumab OR avelumab OR tremelimumab)
#3	TS=(derived neutrophil-lymphocyte ratio OR Dnlr OR derived neutrophil lymphocyte ratio OR derived neutrophil to lymphocyte ratio)
#4	#1 AND #2 AND #3

BMJ Open

Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049123.R1
Article Type:	Original research
Date Submitted by the Author:	14-Apr-2021
Complete List of Authors:	Yang, Tao; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Hao, Lizheng; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital Yang, Xinyu; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital Luo, Changyong; Beijing University of Chinese Medicine Wang, Guomi; Beijing University of Chinese Medicine Lin Cai, Caroline; London College of Chinese Medicine Qi, Shuo; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, oncology department Li, Zhong; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Department of Hematology and Oncology
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Oncology
Keywords:	ONCOLOGY, IMMUNOLOGY, THERAPEUTICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR)**
5
6 **in non-small cell lung cancer patients receiving immune checkpoint**
7
8
9 **inhibitors: a meta-analysis**
10

11 Tao Yang^{1*} Lizheng Hao^{1*} Xinyu Yang¹ Changyong Luo² Guomi Wang³ Caroline
12
13 Lin Cai⁴ Shuo Qi^{5,6} Zhong Li⁷
14

15 1 Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Beijing,
16
17 China
18

19 2 Chinese Medicine College, Beijing University of Chinese Medicine, Beijing, China
20

21 3 Life Science College, Beijing University of Chinese Medicine, Beijing, China
22

23 4 London College of Chinese Medicine, London, UK
24

25 5 Department of Thyroid, Beijing University of Chinese Medicine Affiliated
26
27 Dongzhimen Hospital, Beijing, China
28

29 6 Sun Simiao hospital, Beijing University of Chinese Medicine, Tongchuan, China
30

31 7. Department of Hematology and Oncology, Beijing University of Chinese Medicine
32
33 Affiliated Dongzhimen Hospital, Beijing, China
34

35 Corresponding Author: Zhong Li, PhD, Professor, Email: a2916@bucm.deu.cn;
36
37 Department of Hematology and Oncology, Beijing University of Chinese Medicine
38
39 Affiliated Dongzhimen Hospital, Beijing, China, 100700
40

41 Co-corresponding Author: Shuo Qi, PhD, Email: shuoqi@bucm.edu.cn; Sun Simiao
42
43 hospital, Beijing University of Chinese Medicine, Tongchuan, China, 727100;
44
45 Department of Hematology and Oncology, Beijing University of Chinese Medicine
46
47 Affiliated Dongzhimen Hospital, Beijing, China, 100700
48

49 *These authors contributed equally to this work.
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: Derived neutrophil-to-lymphocytes ratio (dNLR) has recently been reported as a novel potential biomarker in predicting the prognosis of non-small cell lung cancer (NSCLC). However, evidence for the prognostic utility of dNLR in NSCLC patients treated with immune checkpoint inhibitors (ICIs) remains inconsistent. The objective of our meta-analysis was to assess the association of pretreatment dNLR and prognosis of NSCLC patients who were treated with ICIs.

Design: This study followed the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) guidelines.

Data Sources: PubMed, EMBASE, Web of Science, and the Cochrane Library were searched for eligible studies up to 16 October 2020.

Eligibility Criteria: 1) human subjects receiving ICIs therapy and who had been diagnosed with NSCLC; 2) the baseline values of dNLR were obtained; 3) the objective of the study was to investigate the relationships between dNLR and OS or PFS in NSCLC; 4) hazard ratio (HR) and 95% confidence interval (CI) were displayed in the original article or could be extracted from Kaplan-Meier curves.

Data extraction and synthesis:

Two investigators independently extracted data. Data synthesis was performed via systematic review and meta-analysis of eligible cohort studies. Meta-analysis was performed with Cochran's Q test and I^2 statistics. Publication bias of studies was assessed by Begg's test and Egger's test. The STATA statistical software version we used was 12.0.

Results: This analysis included 8 studies (2,456 cases) of the prognostic utility of dNLR in ICI therapy for NSCLC. The results indicate that higher dNLR significantly predicted poor overall survival (OS) (hazard ratio [HR] = 1.65, 95% confidence interval [CI] 1.46–1.88; $P < 0.001$) and progression-free survival (PFS) (HR = 1.38, 95% CI 1.23–1.55; $P < 0.001$). Subgroup analyses of OS-related studies indicated that there were similar results in stratifications by ethnicity, sample size, type of HR, and dNLR cut-off value. As for PFS-related studies, subgroup analyses showed no significant

1
2
3
4 difference in Asian populations. Publication biases were not detected using Begg's test
5
6 and Egger's linear regression test.

7
8 **Conclusions:** This meta-analysis indicated that elevated pretreatment dNLR may be a
9
10 negative prognostic predictor for NSCLC patients treated with ICIs. More large-sample
11
12 and higher quality studies are warranted to support our findings.

13
14 **PROSPERO registration number:** CRD42021214034

15
16 **Keywords:** derived neutrophil-to-lymphocyte ratio, immune checkpoint inhibitors,
17
18 non-small cell lung cancer, meta-analysis

19 20 **Strengths and limitations of this study**

- 21
22 ▶ This is the first study to evaluate the prognostic value of pretreatment dNLR in
23
24 NSCLC patients who treated with ICIs.
- 25
26 ▶ This meta-analysis may provide novel prognostic guidance for NSCLC patients
27
28 treated with ICIs.
- 29
30 ▶ All the studies included in this meta-analysis were retrospective cohort studies, and
31
32 the number of eligible studies was < 10, so there may be some retrospective bias
33
34 and publication bias.

35 36 37 **Introduction**

38
39 Global cancer statistics have shown that there are 1.24 million new cases and 1.09
40
41 million deaths from lung cancer each year.¹ Non-small cell lung cancer (NSCLC)
42
43 accounts for about 85% of primary lung cancers and includes 3 main pathological types:
44
45 squamous cell carcinoma, adenocarcinoma, and large cell lung cancer.² The treatment
46
47 strategy for NSCLC depends on the stage of the cancer. Early stage patients should be
48
49 treated with surgical resection, while advanced stage patients are mainly treated with
50
51 systematic therapy. The five-year survival rates for NSCLC range from 14% to 49% for
52
53 stage I-IIIa patients, and are less than 5% for stage IIIB-IV disease.³ In the past ten
54
55 years, the application of immune checkpoint inhibitors (ICIs) in the treatment of
56
57 NSCLC has improved the therapeutic landscape for this intractable disease. PD-1 and
58
59 PD-L1 inhibitors have shown encouraging results in NSCLC (Pembrolizumab and
60

1
2
3
4 Nivolumab, for instance) and they have been approved by the U.S. Food and Drug
5 Administration (FDA) for the treatment of advanced NSCLC^{4 5}. The latest phase 3
6 study showed that nivolumab was demonstrated a superior OS versus docetaxel at 2
7 years in NSCLC⁶. And a real-life cohort of advanced NSCLC patients treated with
8 pembrolizumab demonstrated similar PFS to the pivotal clinical trial⁷. Some patients
9 with advanced NSCLC have shown overall survival (OS) or progression-free survival
10 (PFS) benefits from ICI treatment after chemoradiotherapy.^{8 9}

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Despite significant clinical improvements, not all ICI treatments are effective in
NSCLC patients. Some valuable biomarkers that predict ICI response, such as
programmed cell death-ligand 1 (PD-L1), tumour mutational burden, and tumour-
infiltrating lymphocytes which could indicate the status of the tumour immune
microenvironment have led to more effective application of ICIs.¹⁰ However, most of
these biomarkers are detected in an invasive manner, which depends heavily on
sufficient tumour tissue. Thus, there is an urgent need to explore and evaluate better
biomarkers for selecting patients suitable for ICI treatment.

Inflammation processes have been proven to be mechanisms of immune resistance in
cancer patients which can promote tumour growth and invasion and activate
carcinogenic signalling pathways.¹¹ In clinical practice, peripheral serum indicators are
used to evaluate systemic inflammation, and some of them are associated with
prognosis and therapeutic response of patients with cancer.^{12 13} The common
haematological inflammatory indicators include white blood cells (WBC), lymphocytes,
and C-reactive protein (CRP). Derived neutrophil-to-lymphocyte ratio (dNLR) is a
novel potential biomarker for systemic inflammation, which can be calculated by
absolute value of neutrophils and value of leucocyte count.¹⁴ DNLR has been used to
assess response to immunotherapy in various cancers, including NSCLC.¹⁵⁻¹⁷ Recent
studies showed the predictive utility of pretreatment dNLR in urological cancer and
breast cancer.^{18 19} However, evidence of the association between the prognosis of
NSCLC and dNLR remains mixed. Therefore, the objective of our study was to explore
the relationship between pretreatment dNLR and survival in NSCLC patients treated

1
2
3
4 with ICIs.

5 **Methods**

7 **Patient and public involvement**

8
9 It was not appropriate or possible to involve patients or the public in the design, conduct,
10 reporting, or dissemination plans of our research.
11

13 **Design**

14
15 This study followed the Preferred Reporting Items for Systematic review and Meta-
16 Analyses (PRISMA) guidelines (supplementary file 1). The protocol is registered at
17 PROSPERO (CRD42021214034).
18

21 **Search strategy and study inclusion**

22
23 Our meta-analysis was conducted to explore the association between dNLR and
24 prognosis of NSCLC patients treated with ICIs. We conducted a search of four
25 electronic journal databases: PubMed, EMBASE, Web of Science, and the Cochrane
26 Library. The search consisted of three parts: 1) the subject words (Emtree in EMBASE
27 and MeSH in other databases) and free words of NSCLC were searched respectively,
28 2) the abbreviations and specific names of ICIs were searched, 3) dNLR and its full
29 name were also searched. The last search was updated on 16 October 2020.
30 (supplementary file 2)
31

32
33 The inclusion criteria were as follows: 1) human subjects receiving ICIs therapy and
34 who had been diagnosed with NSCLC; 2) the baseline values of dNLR were obtained;
35 3) the objective of the study was to investigate the relationships between dNLR and OS
36 or PFS in NSCLC; 4) hazard ratio (HR) and 95% confidence interval (CI) were
37 displayed in the original article or could be extracted from Kaplan-Meier curves.
38

39
40 The exclusion criteria were as follows: (1) studies including subjects with other diseases;
41 (2) case reports, reviews, meta-analyses, conference abstracts, and letters; (3) duplicate
42 publications; (4) we were unable to acquire the full text or data from the text.
43

54 **Quality assessment**

55
56 We evaluated the quality of the included studies using the Newcastle-Ottawa Scale
57 (NOS),²⁰ which assesses three aspects of the studies: selection, comparability, and
58
59
60

1
2
3
4 outcome. Each study could be given a maximum of 9 stars. A higher number of stars
5 indicated better study quality.
6

7 **Data extraction**

8
9 Two investigators independently extracted data. Any disagreement was settled by
10 discussion until agreement was reached or by consulting a third investigator. Data
11 extracted were author, year of publication, study districts, age, sample size, type of ICIs,
12 median follow-up time, cut-off value of dNLR, and clinical stage. As for quantitative
13 data, HRs with 95% CI of OS and PFS were also acquired from the included studies.
14
15

16 **Statistical analysis**

17
18 To evaluate the association between pretreatment dNLR and survival outcomes of the
19 NSCLC patients treated with ICIs, HRs with 95% CI were gathered to give the effective
20 value. We assessed the heterogeneity of the eligible studies by using Cochran's Q test
21 and I^2 statistics. $I^2 > 50\%$ and $P < 0.05$ in the Cochran's Q test were considered to
22 indicate significant heterogeneity, and the random effects model was applied to
23 calculate the pooled HRs. If heterogeneity was not significant, the fixed effects model
24 was utilised. Subgroup analysis was conducted to assess heterogeneity among the
25 results of different studies and explore the stability of results in different stratifications.
26
27 Publication bias of studies was assessed by Begg's test and Egger's test. All P-values
28 were two-sided, and $P < 0.05$ was considered statistically significant. STATA statistical
29 software version 12.0 was used for all statistical analysis in this study.
30
31

32 **Results**

33 **Study characteristics**

34
35 A total of 193 articles were retrieved using the initial search strategies. After multiple
36 screening processes, 8 studies with a total of 2,456 patients, published between 2018
37 and 2020, were finally included in our meta-analysis. The flow chart of study inclusion
38 is shown in Figure 1. Among all studies, participants in 2 studies were Asian^{21 22} and in
39 the other 6 were European or American.^{17 23-27} HRs and 95% CIs were reported exactly
40 in 7 studies,²¹⁻²⁷ while the remaining study¹⁷ reported only HR and P-value; we then
41 estimated 95% CI for that study based on HR and P value.²⁸ The calculation formula is as
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 follows:

$$5 \quad SE = \frac{\log(HR)}{-0.862 + \sqrt{2.404 \times \log(P)}}$$

$$6 \quad \text{Lower 95\%} = e^{\log(HR) - 1.96 \times SE}$$

$$7 \quad \text{Upper 95\%} = e^{\log(HR) + 1.96 \times SE}$$

8
9
10
11
12 This study¹⁷ computed HRs using univariable analysis and the other 7 studies applied
13 multivariable analysis.²¹⁻²⁷ Four of the study cohorts^{17 23-25} enrolled <200 patients and
14 4 cohorts^{21 22 26 27} had >200 patients. The cut-off values of NLR applied in the studies
15 were not consistent, ranging from 2.2 to 3.0. Six studies involved stage III-IV/IIIb-IV
16 cancer, and 2 studies did not clearly report stage.^{17 21} All studies investigated the
17 associations of dNLR and OS, and 7 studies reported the associations of dNLR and
18 PFS. The attributes of the eligible studies are shown in Table 1, and the NOS score of
19 included studies is shown in Table 2.
20
21
22
23
24
25
26
27
28
29

30 Figure 1. Flow chart of the eligible studies
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 1. Main characteristics of all the eligible studies in the meta-analysis

Author	Year	Country	Ethnicity	Age (median and range)	Sample size	ICIs	Cut off value	Stage	Variable	Median follow-up time (months)
Russo A ¹⁷	2018	Italy	European	69(47-78)	28	Nivo	3	NA	U	17
Mezquita L	2018	France	European	NA	305	NA	3	IV	M	12
Prelaj A ²³	2019	Italy	European	67(31-86)	154	Nivo/Pembro	2.2	IIIb-IV	M	NA
Kazandjian D ²⁷	2019	USA	America	NA	1368	NA	3	IV	M	NA
Seban R ²⁴	2020	France	European	65(37-86)	63	Pembro	3	IIIb-IV	M	13.4
Seban R ²⁵	2020	France	European	61.9(34.2-84.8)	109	Nivo/Pembro/Atezo	3	III-IV	M	11.6
Yuan S ²²	2020	China	Asian	66(57-69)	203	Pembro/Nivo/Tori/Sinti/Cam/Tis	2.35	IIIb-IV	M	NA
Takada K ²¹	2020	Japan	Asian	66(31-88)	226	Nivo/Pembro	2.79	NA	M	13.8

NA: not available; Nivo: nivolumab; Pembro: pembrolizumab; Atezo: atezolizumab; Crizo: crizotinib; Sinti: sintilizumab; Tori: toripalimab; Cam: camrelizumab; Tis: tislelizumab; U: univariable; M: multivariable

Table 2. Quality assessment of included studies

Studies	Representativeness of population	Non-respondents	Ascertainment of the exposure	Outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Enough follow-up period	Adequacy of follow-up of cohorts	Total stars
Russo A 2018	☆	☆	☆	☆	☆–	☆	☆	☆	8
Mezquita L 2018	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Prelaj A 2019	☆	☆	☆	☆	☆☆	☆	–	☆	8
Kazandjian D 2019	☆	☆	☆	☆	☆☆	☆	–	☆	8
Seban R 2020	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Seban R 2020	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Yuan S 2020	☆	☆	☆	☆	☆☆	☆	–	☆	8
Takada K 2020	☆	☆	☆	☆	☆☆	☆	☆	☆	9

☆represents the score of the study in this item. –, no star in this item.

Association between pretreatment dNLR and OS in NSCLC

Eight studies with 2,456 patients were finally included in our analysis of the association between pretreatment dNLR and OS. A fixed effects model was applied due to relatively satisfactory homogeneity ($I^2=18.6\%$, 95% CI -71.4%-61.4%, $P = 0.283$). Our pooled result indicated that elevated pretreatment dNLR predicted a worse outcome for OS (HR = 1.65, 95% CI 1.46–1.88; $P < 0.001$) (Figure 2) compared with those with low pretreatment dNLR. In subgroup analyses by ethnicity, the pooled HR was 1.53 (95% CI 1.18–1.98; $P = 0.001$) for Asian patients and 1.70 (95% CI 1.47–1.96; $P < 0.001$) for European or American patients. Stratification by sample size found that dNLR was a negative predictor for OS in both the large sample size group (HR: 1.62, 95% CI 1.42–1.85; $P < 0.001$) and the small sample size group (HR: 2.03, 95% CI 1.33–3.09; $P < 0.001$). In subgroup analyses by cut-off value ≥ 3 and cut-off value < 3 , the data showed that the pooled HR was 1.72 (95% CI 1.49–1.99, $P < 0.001$) for cut-off value ≥ 3 and 1.48 (95% CI 1.15-1.90, $P = 0.002$) for cut-off value < 3 . Subgroup analysis was conducted using univariable and multivariable analysis (Table 3).

Figure 2. Forest plot of the association between pretreatment dNLR and OS

Association between pretreatment dNLR and PFS in NSCLC

Seven studies including 2,151 patients were finally selected for analysis of the association between pretreatment dNLR and PFS. A fixed effects model was adopted due to $I^2=46.5\%$ (95% CI -27.0%-77.4%) and $P=0.082$. The results demonstrated that high pretreatment dNLR was significantly associated with poorer PFS (HR = 1.38, 95% CI 1.23–1.55; $P < 0.001$) (Figure 3) compared with low pretreatment dNLR. Subgroup analysis was performed by ethnicity; the results showed that dNLR was a negative predictor for NSCLC in European or American patients (HR = 1.33, 95% CI 1.14–1.55; $P < 0.001$), but in Asian dNLR and PFS have no significant relationship (HR = 1.57, 95% CI 0.97–2.54; $P = 0.068$). In the small sample size group, the pooled HR was 1.67 (95% CI 1.17–2.37; $P = 0.005$), and in the large sample size group the HR was 1.43 (95% CI

1
2
3
4 1.10–1.85; $P = 0.007$). Subgroup analyses by cut-off value of dNLR showed that the
5 pooled HR was 1.33 (95% CI 1.14-1.55, $P < 0.001$) for cutoff value ≥ 3 and 1.51 (95%
6 CI 1.01-2.26, $P = 0.043$) for cut-off value < 3 . Furthermore, subgroup analysis was
7 conducted using univariable and multivariable analysis, and the results also illustrated
8 the interrelation between baseline dNLR and PFS (Table 3).
9
10
11
12
13
14

15 Figure 3. Forest plot of the association between pretreatment dNLR and PFS
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 3. Summary of the subgroup analysis results in studies with dNLR

Variables	OS					PFS				
	Number of studies	Pooled HR (95% CI)	P	I2	Ph	Number of studies	Pooled HR (95% CI)	P	I2	Ph
Ethnicity										
Asian	2	1.53(1.18,1.98)	0.001	0.00%	0.56	2	1.57(0.97,2.54)	0.068	85.30%	0.009
European/American	6	1.70(1.47,1.96)	0	35.80%	0.169	5	1.33(1.14,1.55)	0	0.00%	0.431
Sample size										
≤200	4	2.03(1.33,3.09)	0	56.90%	0.073	4	1.67(1.17,2.37)	0.005	0.00%	0.598
> 200	4	1.62(1.42,1.85)	0	0.00%	0.883	3	1.43(1.10,1.85)	0.007	75.40%	0.017
Type of analysis										
Univariable	1	-	-	-	-	1	-	-	-	-
Multivariable	7	1.66(1.46,1.88)	0	24.40%	0.243	6	1.39(1.24,1.56)	0	54.00%	0.054
dNLR cut-off value										
<3	3	1.48(1.15,1.90)	0.002	0.00%	0.568	3	1.51(1.01,2.26)	0.043	71.10%	0.031
≥3	5	1.72(1.49,1.99)	0	37.60%	0.17	4	1.33(1.14,1.55)	0	21.00%	0.284

Publication bias

We conducted Begg's and Egger's linear regression test to assess publication bias. OS publication bias was not discovered in studies with dNLR ($Pr>|z|=0.902$ for Begg's test and $P>|t|=0.648$ for Egger's test); publication bias was also not detected for PFS ($Pr>|z|=0.764$ and $P>|t|=0.392$, respectively). The plots of Begg's test and Egger's test are shown in Figure 4.

Figure 4. Funnel plot for analysis of publication bias. (A) Funnel plot established using Begg's test for studies with OS; (B) funnel plot utilising Egger's test for studies with OS. (C) Funnel plot established utilising Begg's test for studies with PFS; (D) funnel plot utilising Egger's test for studies with PFS.

Discussion

This meta-analysis evaluated the results of 2,456 NSCLC patients in 8 studies. The results showed that high level dNLR was a significant predictor of worse OS (HR = 1.65, 95% CI 1.46–1.88; $P < 0.001$) and PFS (HR = 1.38, 95% CI 1.23–1.55; $P < 0.001$) of NSCLC patients treated with ICIs. Subgroup analyses of OS-related studies indicated similar results in stratifications by ethnicity, sample size, type of HR, and dNLR cut-off value. In PFS-related studies, subgroup analyses showed that there was no significant difference in the Asian sample group, but Asian sample subgroup only included 2 studies, which might weaken the credibility of the results of subgroup analysis. We conclude that pretreatment dNLR may be an important biomarker of the prognosis of NSCLC patients treated with ICIs.

Inflammation tends to lead to the development of cancer and stimulates all stages of tumourigenesis through multiple mechanisms.²⁹ Induction of inflammation can bring increased mutagenesis, leading to collection of mutations in normal tissue that can further cause tumour formation.^{30 31} Unlike in earlier stages of oncogenesis, cancer-related inflammation plays a crucial role in regulation of metastasis and leads to worse mortality.³² Additionally, the inflammation process has been suggested as a reason for

1
2
3
4 immune resistance in cancer patients. The cellular effectors of inflammation are
5 significant elements of the tumour microenvironment that break down adaptive immune
6 responses and impede responses to anti-tumour agents.³³ Moreover, a peripheral pro-
7 inflammatory condition has been linked to poor prognosis in patients with cancer¹¹.
8
9 Many routine blood indices including WBC, CRP, absolute neutrophil count, and
10 lactate dehydrogenase level have been evaluated as potential inflammatory biomarkers,
11 which are associated with worse survival in various types of cancer.³⁴⁻³⁶ Novel
12 biomarkers such as NLR, lymphocyte-monocyte ratio (LMR), and lymphocyte-platelet
13 ratio (PLR) have also been used to assess inflammatory status in several cancer types,
14 including NSCLCs.³⁷⁻³⁹ In particular, NLR is a well-studied prognostic predictor in
15 NSCLC patients, and some meta-analyses have confirmed the predictive value of NLR
16 in patients with NSCLC.^{40 41}

17
18 Recent studies indicated that dNLR is a novel serum marker of inflammatory in NSCLC
19 patients treated with ICIs.^{17 42} Although some studies have suggested relationships
20 between NLR and survival and therapeutic outcomes in NSCLC patients treated with
21 anti-PD-1 inhibitors,^{12 43 44} dNLR may be more strongly linked because it includes
22 monocytes and other granulocytes. Immature or poorly differentiated neutrophils can
23 be released in a pro-inflammatory environment, which increases neutrophil generation
24 rapidly. dNLR seems to reflect this negative inflammation more comprehensively. Our
25 study demonstrated that dNLR may be a valuable prognostic serum biomarker for
26 clinicians' decision making in NSCLC ICIs treatment. Future studies should pay more
27 attentions to the prognostic effect of dNLR on the NSCLC patients with ICIs. A larger
28 sample study is needed to verify our results.

29
30 In our study, most included studies have chosen a dNLR cut-off value of 3 to distinguish
31 the prognosis of NSCLC patients treated with ICIs, however, the selection and source
32 of dNLR cut-off values were rarely mentioned in original studies. We performed
33 subgroup analysis according to different dNLR cut-off levels, the results show that
34 significant HR of OS and PFS could be produced by all subgroups. It is also probably
35 necessary to use receiver operating characteristic (ROC) curves or other tools to
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

determine the optimal pretreatment dNLR cut-off value based on large sample data, so that dNLR can be better applied to clinical practice.

Several limitations of our meta-analysis require careful consideration. First, the eligible studies were all retrospective, retrospective study is more prone to several bias including selection recall and measurement biases, so these retrospective biases may influence the accuracy of results. Second, although neither Begg's test nor Egger's test showed publication bias in this study, the effectiveness of the two tests was low when the number of meta-analyses was < 10. In addition, our study mainly searched English-language databases. Hence, publication bias should also be considered.

In conclusion, this meta-analysis revealed that elevated pretreatment dNLR may be a negative prognostic index for NSCLC patients treated with ICIs. Future well-designed and large-scale studies are needed to validate the result.

Acknowledgements

None.

Author contributions

ZL and SQ put forward the idea of research. The search strategy was developed and conducted by TY, LH, and XY. LH and XY independently screened the titles and abstracts of all included studies. Data extraction was performed by LH, XY, CL, and GW. TY and LH conducted the meta-analysis. Manuscript was written by TY and CLC.

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

Not applicable.

Patient consent for publication

Not applicable.

Data availability

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

No additional data available.

For peer review only

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians* 2018;68(6):394-424. doi: 10.3322/caac.21492
2. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. *Mayo Clinic proceedings* 2019;94(8):1623-40. doi: 10.1016/j.mayocp.2019.01.013 [published Online First: 2019/08/06]
3. Ko EC, Raben D, Formenti SC. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. *Clin Cancer Res* 2018;24(23):5792-806. doi: 10.1158/1078-0432.Ccr-17-3620 [published Online First: 2018/06/28]
4. Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. *Ann Oncol* 2018;29(4):959-65. doi: 10.1093/annonc/mdy041 [published Online First: 2018/02/07]
5. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016;387(10027):1540-50. doi: 10.1016/S0140-6736(15)01281-7 [published Online First: 2015/12/30]
6. Lu S, Wang J, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). *Lung Cancer* 2021;152:7-14. doi: 10.1016/j.lungcan.2020.11.013 [published Online First:

- 1
2
3
4 2020/12/16]
- 5
6
7 7. Amrane K, Geier M, Corre R, et al. First-line pembrolizumab for non-small cell lung cancer
8
9 patients with PD-L1 \geq 50% in a multicenter real-life cohort: The PEMBREIZH study.
10
11 *Cancer Med* 2020;9(7):2309-16. doi: 10.1002/cam4.2806 [published Online First:
12
13 2020/02/06]
- 14
15
16
17 8. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III
18
19 Non-Small-Cell Lung Cancer. 2017;377(20):1919.
- 20
21
22 9. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after
23
24 Chemoradiotherapy in Stage III NSCLC. *N Engl J Med* 2018;379(24):2342-50. doi:
25
26 10.1056/NEJMoa1809697 [published Online First: 2018/10/04]
- 27
28
29
30 10. Bodor JN, Bumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-
31
32 small cell lung cancer (NSCLC). *Cancer* 2020;126(2):260-70. doi: 10.1002/cncr.32468
33
34 [published Online First: 2019/11/07]
- 35
36
37
38 11. Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index
39
40 With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small
41
42 Cell Lung Cancer. *JAMA oncology* 2018;4(3):351-57. doi:
43
44 10.1001/jamaoncol.2017.4771 [published Online First: 2018/01/13]
- 45
46
47
48 12. Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a
49
50 marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung
51
52 cancer. *Lung Cancer* 2017;106:1-7. doi: 10.1016/j.lungcan.2017.01.013 [published
53
54 Online First: 2017/03/14]
- 55
56
57
58 13. Pine JK, Morris E, Hutchins GG, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal
59
60

- 1
2
3
4 cancer: the relationship to patient survival, tumour biology and local lymphocytic
5
6 response to tumour. *Br J Cancer* 2015;113(2):204-11. doi: 10.1038/bjc.2015.87
7
8
9 [published Online First: 2015/07/01]
10
11
12 14. Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio
13
14 predicts survival in patients with cancer. *Br J Cancer* 2012;107(4):695-9. doi:
15
16 10.1038/bjc.2012.292 [published Online First: 2012/07/26]
17
18
19 15. Afzal MZ, Sarwar T, Shirai K. Prognostic Significance of Hematological Indices in Malignant
20
21 Melanoma Treated With Immune Checkpoint Inhibitors. *J Immunother* 2019;42(7):251-
22
23 64. doi: 10.1097/cji.0000000000000272 [published Online First: 2019/05/31]
24
25
26
27 16. Bruixola G, Caballero J, Papaccio F, et al. Prognostic Nutritional Index as an independent
28
29 prognostic factor in locoregionally advanced squamous cell head and neck cancer.
30
31 *ESMO open* 2018;3(6):e000425. doi: 10.1136/esmoopen-2018-000425 [published
32
33 Online First: 2018/11/15]
34
35
36
37 17. Russo A, Franchina T, Ricciardi GRR, et al. Baseline neutrophilia, derived neutrophil-to-
38
39 lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small
40
41 cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. *Journal of cellular*
42
43 *physiology* 2018;233(10):6337-43. doi: 10.1002/jcp.26609
44
45
46
47
48 18. Su S, Liu L, Li C, et al. Prognostic role of pretreatment derived neutrophil to lymphocyte
49
50 ratio in urological cancers: A systematic review and meta-analysis. *International journal*
51
52 *of surgery (London, England)* 2019;72:146-53. doi: 10.1016/j.ijso.2019.10.043
53
54
55
56 [published Online First: 2019/11/11]
57
58
59 19. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and
60


- 1
2
3
4 derived NLR are associated with poor prognosis in patients with breast cancer: A meta-
5
6 analysis. *Medicine* 2018;97(49):e13340. doi: 10.1097/md.00000000000013340
7
8 [published Online First: 2018/12/14]
9
10
11 20. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies
12
13 in Meta-Analyses. Symposium on Systematic Reviews: Beyond the Basics; 2014.
14
15
16
17 21. Takada K, Takamori S, Yoneshima Y, et al. Serum markers associated with treatment
18
19 response and survival in non-small cell lung cancer patients treated with anti-PD-1
20
21 therapy. *Lung Cancer* 2020;145:18-26. doi: 10.1016/j.lungcan.2020.04.034
22
23
24
25 22. Yuan S, Xia Y, Shen L, et al. Development of nomograms to predict therapeutic response
26
27 and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.
28
29
30
31 *Cancer Immunology, Immunotherapy* 2020 doi: 10.1007/s00262-020-02710-9
32
33
34 23. Prelaj A, Rebuzzi SE, Pizzutilo P, et al. EPSILoN: A Prognostic Score Using Clinical and
35
36 Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With
37
38 Immunotherapy. *Clinical lung cancer* 2020;21(4):365-77.e5. doi:
39
40 10.1016/j.clc.2019.11.017 [published Online First: 2020/04/05]
41
42
43 24. Seban RD, Assié JB, Giroux-Ieprieur E, et al. Association of the metabolic score using
44
45 baseline FDG-PET/CT and DNLR with immunotherapy outcomes in advanced NSCLC
46
47 patients treated with first - line pembrolizumab. *Cancers* 2020;12(8):1-14. doi:
48
49 10.3390/cancers12082234
50
51
52
53 25. Seban RD, Mezquita L, Berenbaum A, et al. Baseline metabolic tumor burden on FDG
54
55 PET/CT scans predicts outcome in advanced NSCLC patients treated with immune
56
57 checkpoint inhibitors. *European journal of nuclear medicine and molecular imaging*
58
59
60

- 2020;47(5):1147-57. doi: 10.1007/s00259-019-04615-x
26. Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *JAMA oncology* 2018;4(3):351-57. doi: 10.1001/jamaoncol.2017.4771
27. Kazandjian D, Gong Y, Keegan P, et al. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer. *JAMA oncology* 2019;5(10):1481-85. doi: 10.1001/jamaoncol.2019.1747
28. Altman DG, Bland JM. How to obtain the confidence interval from a P value. *BMJ* 2011;343:d2090. doi: 10.1136/bmj.d2090 [published Online First: 2011/08/10]
29. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. *Immunity* 2019;51(1):27-41. doi: 10.1016/j.immuni.2019.06.025 [published Online First: 2019/07/18]
30. Canli Ö, Nicolas AM, Gupta J, et al. Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis. *Cancer cell* 2017;32(6):869-83.e5. doi: 10.1016/j.ccell.2017.11.004 [published Online First: 2017/12/13]
31. Robles AI, Traverso G, Zhang M, et al. Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. *Gastroenterology* 2016;150(4):931-43. doi: 10.1053/j.gastro.2015.12.036 [published Online First: 2016/01/15]
32. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *Lancet* 2012;379(9826):1591-601. doi: 10.1016/s0140-6736(12)60209-8 [published Online

- 1
2
3
4 First: 2012/03/24]
5
6
7 33. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. *Nature*
8
9 2008;454(7203):436-44. doi: 10.1038/nature07205 [published Online First: 2008/07/25]
10
11
12 34. Soyano AE, Dholaria B, Marin-Acevedo JA, et al. Peripheral blood biomarkers correlate
13
14 with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1
15
16 antibodies. *J Immunother Cancer* 2018;6(1):129. doi: 10.1186/s40425-018-0447-2
17
18 [published Online First: 2018/11/25]
19
20
21
22 35. Wang H, Wang MS, Zhou YH, et al. Prognostic Values of LDH and CRP in Cervical Cancer.
23
24 *OncoTargets and therapy* 2020;13:1255-63. doi: 10.2147/ott.S235027 [published
25
26 Online First: 2020/02/28]
27
28
29
30 36. Yoon CI, Park S, Cha YJ, et al. Associations between absolute neutrophil count and
31
32 lymphocyte-predominant breast cancer. *Breast (Edinburgh, Scotland)* 2020;50:141-48.
33
34 doi: 10.1016/j.breast.2019.09.013 [published Online First: 2019/10/15]
35
36
37
38 37. Xiao X, Wang S, Long G. C-reactive protein is a significant predictor of improved survival
39
40 in patients with advanced non-small cell lung cancer. *Medicine* 2019;98(26):e16238.
41
42 doi: 10.1097/md.00000000000016238 [published Online First: 2019/07/03]
43
44
45
46 38. Machado D, Marques C, Dias M, et al. Inflammatory prognostic biomarkers in advanced
47
48 non-small cell lung cancer. *Pulmonology* 2019;25(3):181-83. doi:
49
50 10.1016/j.pulmoe.2019.02.007 [published Online First: 2019/04/03]
51
52
53
54 39. Cedrés S, Torrejon D, Martínez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator
55
56 of poor prognosis in stage IV non-small cell lung cancer. *Clin Transl Oncol*
57
58 2012;14(11):864-9. doi: 10.1007/s12094-012-0872-5 [published Online First:
59
60


1
2
3
4 2012/08/03]
5

- 6
7 40. Wang Z, Zhan P, Lv Y, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio
8
9 in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis.
10
11 *Translational lung cancer research* 2019;8(3):214-26. doi: 10.21037/tlcr.2019.06.10
12
13 [published Online First: 2019/08/02]
14
15
16
17 41. Benedict SD, Anne LJ, Dennis SJO, et al. Prognostic utility of baseline neutrophil-to-
18
19 lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-
20
21 analysis. 2018;Volume 11:955-65.
22
23
24
25 42. Blanc-Durand F, Auclin E, Planchard D, et al. Association of lung immune prognostic index
26
27 (LIPI) with survival of first line immune checkpoint inhibitors single agent or in
28
29 combination with chemotherapy in untreated advanced NSCLC patients. *Annals of*
30
31 *Oncology* 2019;30:xi5. doi: 10.1093/annonc/mdz447.015
32
33
34
35 43. Park W, Lopes G. Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker
36
37 in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer. *Clinical lung cancer*
38
39 2019;20(3):143-47. doi: 10.1016/j.clcc.2018.12.003 [published Online First: 2019/01/27]
40
41
42
43 44. Jiang T, Bai Y, Zhou F, et al. Clinical value of neutrophil-to-lymphocyte ratio in patients with
44
45 non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. *Lung Cancer*
46
47 2019;130:76-83. doi: 10.1016/j.lungcan.2019.02.009 [published Online First:
48
49 2019/03/20]
50
51
52
53
54
55
56
57
58
59
60



Flow chart of the eligible studies


181x245mm (150 x 150 DPI)



Forest plot of the association between pretreatment dNLR and OS

456x326mm (72 x 72 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Forest plot of the association between pretreatment dNLR and PFS

464x327mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Funnel plot for analysis of publication bias



PRISMA 2020 for Abstracts Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	6



PRISMA 2020 for Abstracts Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7-8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	13
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14-15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	15

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.



PRISMA 2020 for Abstracts Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	Yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Yes
Synthesis of results	6	Specify the methods used to present and synthesise results.	Yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	No
Registration	12	Provide the register name and registration number.	Yes

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

Supplementary Table 1 Search strategies for PubMed, Embase, Cochrane Library and Web of science

Database	Keywords
PubMed	
#1	"Carcinoma, Non-Small-Cell Lung"[Mesh]
#2	(Carcinoma, Non Small Cell Lung[Title/Abstract]) OR (Carcinomas, Non-Small-Cell Lung[Title/Abstract]) OR (Lung Carcinoma, Non-Small-Cell[Title/Abstract]) OR (Lung Carcinomas, Non-Small-Cell[Title/Abstract]) OR (Non-Small-Cell Lung Carcinomas[Title/Abstract]) OR (Nonsmall Cell Lung Cancer[Title/Abstract]) OR (Non-Small-Cell Lung Carcinoma[Title/Abstract]) OR (Non Small Cell Lung Carcinoma[Title/Abstract]) OR (Carcinoma, Non-Small Cell Lung[Title/Abstract]) OR (Non-Small Cell Lung Cancer[Title/Abstract])
#3	#1 OR #2
#4	(checkpoint*[Title/Abstract]) OR ("checkpoint inhibitor"[Title/Abstract]) OR (CTLA-4[Title/Abstract]) OR (PD-1[Title/Abstract]) OR (PD-L1[Title/Abstract]) OR (ipilimumab[Title/Abstract]) OR (atezolizumab[Title/Abstract]) OR (durvalumab[Title/Abstract]) OR (pembrolizumab[Title/Abstract]) OR (nivolumab[Title/Abstract]) OR (avelumab[Title/Abstract]) OR (tremelimumab[Title/Abstract])
#5	(derived neutrophil-lymphocyte ratio[Title/Abstract]) OR (dNLR[Title/Abstract]) OR (derived neutrophil lymphocyte ratio[Title/Abstract]) OR (derived neutrophil to lymphocyte ratio[Title/Abstract])
#6	#3 AND #4 AND #5
Embase	
#1	'non small cell lung cancer'/exp
#2	'carcinoma, non small cell lung':ab,ti OR 'carcinomas, non-small-cell lung':ab,ti OR 'lung carcinoma, non-small-cell':ab,ti OR 'lung carcinomas, non-small-cell':ab,ti OR 'non-small-cell lung carcinomas ':ab,ti OR 'non small cell lung cancer':ab,ti OR 'non-small-cell lung carcinoma':ab,ti OR 'non small cell lung carcinoma ':ab,ti OR 'carcinoma, non-small cell lung':ab,ti OR 'non-small cell lung cancer':ab,ti
#3	#1 OR #2
#4	'checkpoint*':ab,ti OR 'checkpoint inhibitor':ab,ti OR 'ctla-4':ab,ti OR 'pd-1':ab,ti OR 'pd-11':ab,ti OR 'ipilimumab':ab,ti OR 'atezolizumab':ab,ti OR 'durvalumab':ab,ti OR 'pembrolizumab':ab,ti OR 'nivolumab':ab,ti OR 'avelumab':ab,ti OR 'tremelimumab':ab,ti
#5	'derived neutrophil-lymphocyte ratio':ab,ti OR 'dnlr':ab,ti OR 'derived neutrophil lymphocyte ratio':ab,ti OR 'derived neutrophil to lymphocyte ratio':ab,ti
#6	#3 AND #4 AND #5
Cochrane Library	
#1	MeSH: Carcinoma, Non-Small-Cell Lung

#2	(Carcinoma, Non Small Cell Lung):ti,ab,kw OR (Carcinomas, Non-Small-Cell Lung):ti,ab,kw OR (Lung Carcinoma, Non-Small-Cell):ti,ab,kw OR (Lung Carcinomas, Non-Small-Cell):ti,ab,kw OR (Non-Small-Cell Lung Carcinomas):ti,ab,kw OR (Non small Cell Lung Cancer):ti,ab,kw OR (Non-Small-Cell Lung Carcinoma):ti,ab,kw OR (Non Small Cell Lung Carcinoma):ti,ab,kw OR (Carcinoma, Non-Small Cell Lung):ti,ab,kw OR (Non-Small Cell Lung Cancer):ti,ab,kw
#3	#1 OR #2
#4	(checkpoint*):ti,ab,kw OR (checkpoint inhibitor):ti,ab,kw OR (CTLA-4):ti,ab,kw OR (PD-1):ti,ab,kw OR (PD-L1):ti,ab,kw OR (ipilimumab):ti,ab,kw OR (atezolizumab):ti,ab,kw OR (durvalumab):ti,ab,kw OR (pembrolizumab):ti,ab,kw OR (nivolumab):ti,ab,kw OR (avelumab):ti,ab,kw OR (tremelimumab):ti,ab,kw
#5	(derived neutrophil-lymphocyte ratio):ti,ab,kw OR (dNLR):ti,ab,kw OR (derived neutrophil lymphocyte ratio):ti,ab,kw OR (derived neutrophil to lymphocyte ratio):ti,ab,kw
#6	#3 AND #4 AND #5
Web of science	
#1	TS=(Carcinoma, Non-Small-Cell Lung OR Carcinoma, Non Small Cell Lung OR Carcinomas, Non-Small-Cell Lung OR Lung Carcinoma, Non-Small-Cell OR Lung Carcinomas, Non-Small-Cell OR Non-Small-Cell Lung Carcinomas OR Non small Cell Lung Cancer OR Non-Small-Cell Lung Carcinoma OR Non Small Cell Lung Carcinoma OR Carcinoma, Non-Small Cell Lung OR Non-Small Cell Lung Cancer)
#2	TS=(checkpoint* OR checkpoint inhibitor OR CTLA-4 OR PD-1 OR PD-L1 OR ipilimumab OR atezolizumab OR durvalumab OR pembrolizumab OR nivolumab OR avelumab OR tremelimumab)
#3	TS=(derived neutrophil-lymphocyte ratio OR Dnlr OR derived neutrophil lymphocyte ratio OR derived neutrophil to lymphocyte ratio)
#4	#1 AND #2 AND #3

BMJ Open

Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049123.R2
Article Type:	Original research
Date Submitted by the Author:	16-Jun-2021
Complete List of Authors:	Yang, Tao; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Hao, Lizheng; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital Yang, Xinyu; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital Luo, Changyong; Beijing University of Chinese Medicine Wang, Guomi; Beijing University of Chinese Medicine Lin Cai, Caroline; London College of Chinese Medicine Qi, Shuo; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, oncology department Li, Zhong; Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Department of Hematology and Oncology
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Oncology
Keywords:	ONCOLOGY, IMMUNOLOGY, THERAPEUTICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR)**
5
6 **in non-small cell lung cancer patients receiving immune checkpoint**
7
8
9 **inhibitors: a meta-analysis**
10

11 Tao Yang^{1*} Lizheng Hao^{1*} Xinyu Yang¹ Changyong Luo² Guomi Wang³ Caroline
12
13 Lin Cai⁴ Shuo Qi^{5,6} Zhong Li⁷
14

15 1 Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Beijing,
16
17 China
18

19 2 Chinese Medicine College, Beijing University of Chinese Medicine, Beijing, China
20

21 3 Life Science College, Beijing University of Chinese Medicine, Beijing, China
22

23 4 London College of Chinese Medicine, London, UK
24

25 5 Department of Thyroid, Beijing University of Chinese Medicine Affiliated
26
27 Dongzhimen Hospital, Beijing, China
28

29 6 Sun Simiao hospital, Beijing University of Chinese Medicine, Tongchuan, China
30

31 7. Department of Hematology and Oncology, Beijing University of Chinese Medicine
32
33 Affiliated Dongzhimen Hospital, Beijing, China
34

35 Corresponding Author: Zhong Li, PhD, Professor, Email: a2916@bucm.deu.cn;
36
37 Department of Hematology and Oncology, Beijing University of Chinese Medicine
38
39 Affiliated Dongzhimen Hospital, Beijing, China, 100700
40

41 Co-corresponding Author: Shuo Qi, PhD, Email: shuoqi@bucm.edu.cn; Sun Simiao
42
43 hospital, Beijing University of Chinese Medicine, Tongchuan, China, 727100;
44
45 Department of Hematology and Oncology, Beijing University of Chinese Medicine
46
47 Affiliated Dongzhimen Hospital, Beijing, China, 100700
48

49 *These authors contributed equally to this work.
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: Derived neutrophil-to-lymphocytes ratio (dNLR) has recently been reported as a novel potential biomarker associated with prognosis of non-small cell lung cancer (NSCLC). However, evidence for the prognostic utility of dNLR in NSCLC patients treated with immune checkpoint inhibitors (ICIs) remains inconsistent. The objective of this work was to evaluate the association between pretreatment dNLR and prognosis of NSCLC patients treated with ICIs.

Design: This study followed the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) guidelines (supplementary file 1).

Data Sources: PubMed, EMBASE, Web of Science, and the Cochrane Library were searched for eligible studies up to 16 October 2020.

Eligibility Criteria: 1) human subjects receiving ICIs therapy and who had been diagnosed with NSCLC; 2) the baseline values of dNLR were obtained; 3) the objective of the study was to investigate the relationships between dNLR and OS or PFS in NSCLC; 4) hazard ratio (HR) and 95% confidence interval (CI) were displayed in the original article or could be extracted from Kaplan-Meier curves.

Data extraction and synthesis:

Two investigators extracted data independently. Data synthesis was performed via systematic review and meta-analysis of eligible cohort studies. Meta-analysis was performed with Cochran's Q test and I^2 statistics. Publication bias of studies was assessed by Begg's test and Egger's test. We used version 12.0 of the Stata statistical software.

Results: This analysis included 8 studies (2,456 cases) on the prognostic utility of dNLR in ICI therapy for NSCLC. The results indicate that higher dNLR significantly predicted poor overall survival (OS) (hazard ratio [HR] = 1.65, 95% confidence interval [CI] 1.46–1.88; $P < 0.001$) and progression-free survival (PFS) (HR = 1.38, 95% CI 1.23–1.55; $P < 0.001$). Subgroup analyses of OS-related studies indicated that there were similar results in stratifications by ethnicity, sample size, type of HR, and dNLR cut-off value. As for PFS-related studies, subgroup analyses showed no significant

1
2
3
4 difference in Asian populations. Publication biases were not detected using Begg's test
5 and Egger's linear regression test.
6

7
8 **Conclusions:** This meta-analysis indicated that elevated pretreatment dNLR may be a
9 negative prognostic predictor for NSCLC patients treated with ICIs. More large-sample
10 and higher quality studies are warranted to support our findings.
11

12
13 **PROSPERO registration number:** CRD42021214034
14

15 **Keywords:** derived neutrophil-to-lymphocyte ratio, immune checkpoint inhibitors,
16 non-small cell lung cancer, meta-analysis
17

18 19 **Strengths and limitations of this study**

- 20
21 ▶ This is the first study to evaluate the prognostic value of pretreatment dNLR in
22 NSCLC patients who treated with ICIs.
23
24 ▶ This meta-analysis may provide novel prognostic guidance for NSCLC patients
25 treated with ICIs.
26
27 ▶ All the studies included in this meta-analysis were retrospective cohort studies, and
28 the number of eligible studies was < 10, so there may be some retrospective bias
29 and publication bias.
30
31
32
33
34
35
36

37 **Introduction**

38
39 Worldwide, lung cancer remains the leading cause of cancer death, with an estimated
40 2.2 million new cases and 1.8 million deaths in 2020¹. Non-small cell lung cancer
41 (NSCLC) accounts for about 85% of primary lung cancers and includes 3 main
42 pathological types: squamous cell carcinoma, adenocarcinoma, and large cell lung
43 cancer.² The treatment strategy for NSCLC depends on the stage of the cancer. Early-
44 stage patients should be treated with surgical resection, while advanced-stage patients
45 are mainly treated with systematic therapy. The five-year survival rates for NSCLC
46 range from 14% to 49% for stage I-IIIa patients, and are less than 5% for stage IIIB-
47 IV disease.³ In the past ten years, the application of immune checkpoint inhibitors (ICIs)
48 in the treatment of NSCLC has improved the therapeutic landscape for this intractable
49 disease. PD-1 and PD-L1 inhibitors have shown encouraging results in NSCLC
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 (Pembrolizumab and Nivolumab, for instance) and they have been approved by the U.S.
5 Food and Drug Administration (FDA) for the treatment of advanced NSCLC^{4 5}. The
6 latest phase 3 study showed that nivolumab was demonstrated a superior OS versus
7 docetaxel at 2 years in NSCLC⁶. And a real-life cohort of advanced NSCLC patients
8 treated with pembrolizumab demonstrated similar PFS to the pivotal clinical trial⁷.
9 Some patients with advanced NSCLC have shown overall survival (OS) or progression-
10 free survival (PFS) benefits from ICI treatment after chemoradiotherapy.^{8 9}

11
12
13
14
15
16
17 Despite significant clinical improvements, not all ICI treatments are effective in
18 NSCLC patients. Some valuable biomarkers that predict ICI response, such as
19 programmed cell death-ligand 1 (PD-L1), tumour mutational burden, and tumour-
20 infiltrating lymphocytes which could indicate the status of the tumour immune
21 microenvironment have led to more effective application of ICIs.¹⁰ However, most of
22 these biomarkers are detected in an invasive manner, which depends heavily on
23 sufficient tumour tissue. Thus, there is an urgent need to explore and evaluate better
24 biomarkers for selecting patients suitable for ICI treatment.

25
26
27
28
29
30
31
32
33 Inflammation processes have been proven to be mechanisms of immune resistance in
34 cancer patients which can promote tumour growth and invasion and activate
35 carcinogenic signalling pathways.¹¹ In clinical practice, peripheral serum indicators are
36 used to evaluate systemic inflammation, and some of them are associated with
37 prognosis and therapeutic response of patients with cancer.^{12 13} The common
38 haematological inflammatory indicators include white blood cells (WBC), lymphocytes,
39 and C-reactive protein (CRP). Derived neutrophil-to-lymphocyte ratio (dNLR) is a
40 novel potential biomarker for systemic inflammation, which can be calculated by
41 absolute value of neutrophils and value of leucocyte count.¹⁴ DNLR has been used to
42 assess response to immunotherapy in various cancers, including NSCLC.¹⁵⁻¹⁷ Recent
43 studies showed the predictive utility of pretreatment dNLR in urological cancer and
44 breast cancer.^{18 19} However, evidence of the association between the prognosis of
45 NSCLC and dNLR remains mixed. Therefore, the objective of our study was to explore
46 the relationship between pretreatment dNLR and survival in NSCLC patients treated
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 with ICIs.

5 **Methods**

7 **Patient and public involvement**

8
9 It was not appropriate or possible to involve patients or the public in the design, conduct,
10 reporting, or dissemination plans of our research.
11

13 **Design**

14
15 This study followed the Preferred Reporting Items for Systematic review and Meta-
16 Analyses (PRISMA) guidelines (supplementary file 1). The protocol is registered at
17 PROSPERO (CRD42021214034).
18

21 **Search strategy and study inclusion**

22
23 Our meta-analysis was conducted to explore the association between dNLR and
24 prognosis of NSCLC patients treated with ICIs. We conducted a search of four
25 electronic journal databases: PubMed, EMBASE, Web of Science, and the Cochrane
26 Library. The search consisted of three parts: 1) the subject words (Emtree in EMBASE
27 and MeSH in other databases) and free words of NSCLC were searched respectively,
28 2) the abbreviations and specific names of ICIs were searched, 3) dNLR and its full
29 name were also searched. The last search was updated on 16 October 2020.
30 (supplementary file 2)
31

32
33 The inclusion criteria were as follows: 1) human subjects receiving ICIs therapy and
34 who had been diagnosed with NSCLC; 2) the baseline values of dNLR were obtained;
35 3) the objective of the study was to investigate the relationships between dNLR and OS
36 or PFS in NSCLC; 4) hazard ratio (HR) and 95% confidence interval (CI) were
37 displayed in the original article or could be extracted from Kaplan-Meier curves.
38

39
40 The exclusion criteria were as follows: (1) studies including subjects with other diseases;
41 (2) case reports, reviews, meta-analyses, conference abstracts, and letters; (3) duplicate
42 publications; (4) we were unable to acquire the full text or data from the text.
43

54 **Quality assessment**

55
56 We evaluated the quality of the included studies using the Newcastle-Ottawa Scale
57 (NOS),²⁰ which assesses three aspects of the studies: selection, comparability, and
58
59
60

1
2
3
4 outcome. Each study could be given a maximum of 9 stars. A higher number of stars
5 indicated better study quality.

6 7 **Data extraction**

8
9 Two investigators independently extracted data. Any disagreement was settled by
10 discussion until agreement was reached or by consulting a third investigator. Data
11 extracted were author, year of publication, study districts, age, sample size, type of ICIs,
12 median follow-up time, cut-off value of dNLR, and clinical stage. As for quantitative
13 data, HRs with 95% CI of OS and PFS were also acquired from the included studies.

14 15 16 17 18 19 **Statistical analysis**

20
21 To evaluate the association between pretreatment dNLR and survival outcomes of the
22 NSCLC patients treated with ICIs, HRs with 95% CI were gathered to give the effective
23 value. We assessed the heterogeneity of the eligible studies by using Cochran's Q test
24 and I^2 statistics. $I^2 > 50\%$ and $P < 0.05$ in the Cochran's Q test were considered to
25 indicate significant heterogeneity, and the random effects model was applied to
26 calculate the pooled HRs. If heterogeneity was not significant, the fixed effects model
27 was utilised. Subgroup analysis was conducted to assess heterogeneity among the
28 results of different studies and explore the stability of results in different stratifications.
29 Publication bias of studies was assessed by Begg's test and Egger's test. All P-values
30 were two-sided, and $P < 0.05$ was considered statistically significant. STATA statistical
31 software version 12.0 was used for all statistical analysis in this study.

32 33 34 35 36 37 38 39 40 41 42 **Results**

43 44 **Study characteristics**

45
46 A total of 193 articles were retrieved using the initial search strategies. After multiple
47 screening processes, 8 studies with a total of 2,456 patients, published between 2018
48 and 2020, were finally included in our meta-analysis. The flow chart of study inclusion
49 is shown in Figure 1. Among all studies, participants in 2 studies were Asian^{21 22} and in
50 the other 6 were European or American.^{17 23-27} HRs and 95% CIs were reported exactly
51 in 7 studies,²¹⁻²⁷ while the remaining study¹⁷ reported only HR and P-value; we then
52 estimated 95% CI for that study based on HR and P value.²⁸ The calculation formula is as
53
54
55
56
57
58
59
60

1
2
3
4 follows:

$$5 \quad SE = \frac{\log(HR)}{-0.862 + \sqrt{2.404 \times \log(P)}}$$

$$6 \quad \text{Lower 95\%} = e^{\log(HR) - 1.96 \times SE}$$

$$7 \quad \text{Upper 95\%} = e^{\log(HR) + 1.96 \times SE}$$

8
9
10
11
12 This study¹⁷ computed HRs using univariable analysis and the other 7 studies applied
13 multivariable analysis.²¹⁻²⁷ Four of the study cohorts^{17 23-25} enrolled <200 patients and
14 4 cohorts^{21 22 26 27} had >200 patients. The cut-off values of NLR applied in the studies
15 were not consistent, ranging from 2.2 to 3.0. Six studies involved stage III-IV/IIIb-IV
16 cancer, and 2 studies did not clearly report stage.^{17 21} All studies investigated the
17 associations of dNLR and OS, and 7 studies reported the associations of dNLR and
18 PFS. The attributes of the eligible studies are shown in Table 1, and the NOS score of
19 included studies is shown in Table 2.
20
21
22
23
24
25
26
27
28
29

30 Figure 1. Flow chart of the eligible studies
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 1. Main characteristics of all the eligible studies in the meta-analysis

Author	Year	Country	Ethnicity	Age (median and range)	Sample size	ICIs	Cut off value	Stage	Variable	Median follow-up time (months)
Russo A ¹⁷	2018	Italy	European	69(47-78)	28	Nivo	3	NA	U	17
Mezquita L	2018	France	European	NA	305	NA	3	IV	M	12
Prelaj A ²³	2019	Italy	European	67(31-86)	154	Nivo/Pembro	2.2	IIIb-IV	M	NA
Kazandjian D ²⁷	2019	USA	America	NA	1368	NA	3	IV	M	NA
Seban R ²⁴	2020	France	European	65(37-86)	63	Pembro	3	IIIb-IV	M	13.4
Seban R ²⁵	2020	France	European	61.9(34.2-84.8)	109	Nivo/Pembro/Atezo	3	III-IV	M	11.6
Yuan S ²²	2020	China	Asian	66(57-69)	203	Pembro/Nivo/Tori/Sinti/Cam/Tis	2.35	IIIb-IV	M	NA
Takada K ²¹	2020	Japan	Asian	66(31-88)	226	Nivo/Pembro	2.79	NA	M	13.8

NA: not available; Nivo: nivolumab; Pembro: pembrolizumab; Atezo: atezolizumab; Crizo: crizotinib; Sinti: sintilizumab; Tori: toripalimab; Cam: camrelizumab; Tis: tislelizumab; U: univariable; M: multivariable

Table 2. Quality assessment of included studies

Studies	Representativeness of population	Non-respondents	Ascertainment of the exposure	Outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Enough follow-up period	Adequacy of follow-up of cohorts	Total stars
Russo A 2018	☆	☆	☆	☆	☆–	☆	☆	☆	8
Mezquita L 2018	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Prelaj A 2019	☆	☆	☆	☆	☆☆	☆	–	☆	8
Kazandjian D 2019	☆	☆	☆	☆	☆☆	☆	–	☆	8
Seban R 2020	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Seban R 2020	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Yuan S 2020	☆	☆	☆	☆	☆☆	☆	–	☆	8
Takada K 2020	☆	☆	☆	☆	☆☆	☆	☆	☆	9

☆represents the score of the study in this item. –, no star in this item.

Association between pretreatment dNLR and OS in NSCLC

Eight studies with 2,456 patients were finally included in our analysis of the association between pretreatment dNLR and OS. A fixed effects model was applied due to relatively satisfactory homogeneity ($I^2=18.6%$, [95% CI (-71.4%~61.4%)], $P = 0.283$). Our pooled result indicated that elevated pretreatment dNLR predicted a worse outcome for OS (HR = 1.65, [95% CI (1.46~1.88)]; $P < 0.001$) (Figure 2) compared with those with low pretreatment dNLR. In subgroup analyses by ethnicity, the pooled HR was 1.53 ([95% CI (1.18~1.98)]; $P = 0.001$) for Asian patients and 1.70 ([95% CI (1.47~1.96)]; $P < 0.001$) for European or American patients. Stratification by sample size found that dNLR was a negative predictor for OS in both the large sample size group (HR: 1.62, [95% CI (1.42~1.85)]; $P < 0.001$) and the small sample size group (HR: 2.03, 95% CI 1.33~3.09; $P < 0.001$). In subgroup analyses by cut-off value ≥ 3 and cut-off value < 3 , the data showed that the pooled HR was 1.72 ([95% CI (1.49~1.99)], $P < 0.001$) for cut-off value ≥ 3 and 1.48 ([95% CI (1.15~1.90)], $P = 0.002$) for cut-off value < 3 . Subgroup analysis was conducted using univariable and multivariable analysis (Table 3).

Figure 2. Forest plot of the association between pretreatment dNLR and OS

Association between pretreatment dNLR and PFS in NSCLC

Seven studies including 2,151 patients were finally selected for analysis of the association between pretreatment dNLR and PFS. A fixed effects model was adopted due to $I^2=46.5%$ [95% CI (-27.0%~77.4%)] and $P=0.082$. The results demonstrated that high pretreatment dNLR was significantly associated with poorer PFS (HR = 1.38, [95% CI (1.23~1.55)]; $P < 0.001$) (Figure 3) compared with low pretreatment dNLR. Subgroup analysis was performed by ethnicity; the results showed that dNLR was a negative predictor for NSCLC in European or American patients (HR = 1.33, [95% CI (1.14~1.55)]; $P < 0.001$), but in Asian dNLR and PFS have no significant relationship (HR = 1.57, [95% CI (0.97~2.54)]; $P = 0.068$). In the small sample size group, the pooled HR

1
2
3
4 was 1.67 ([95% CI (1.17~2.37)]; P = 0.005), and in the large sample size group the HR
5 was 1.43 ([95% CI (1.10~1.85)]; P = 0.007). Subgroup analyses by cut-off value of
6 dNLR showed that the pooled HR was 1.33 ([95% CI (1.14~1.55)], P < 0.001) for cutoff
7 value ≥ 3 and 1.51 ([95% CI (1.01~2.26)], P = 0.043) for cut-off value < 3. Furthermore,
8 subgroup analysis was conducted using univariable and multivariable analysis, and the
9 results also illustrated the interrelation between baseline dNLR and PFS (Table 3).
10
11
12
13
14
15
16

17 Figure 3. Forest plot of the association between pretreatment dNLR and PFS
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 3. Summary of the subgroup analysis results in studies with dNLR

Variables	OS					PFS				
	Number of studies	Pooled HR (95% CI)	P	I2	Ph	Number of studies	Pooled HR (95% CI)	P	I2	Ph
Ethnicity										
Asian	2	1.53(1.18,1.98)	0.001	0.00%	0.56	2	1.57(0.97,2.54)	0.068	85.30%	0.009
European/American	6	1.70(1.47,1.96)	0	35.80%	0.169	5	1.33(1.14,1.55)	0	0.00%	0.431
Sample size										
≤200	4	2.03(1.33,3.09)	0	56.90%	0.073	4	1.67(1.17,2.37)	0.005	0.00%	0.598
> 200	4	1.62(1.42,1.85)	0	0.00%	0.883	3	1.43(1.10,1.85)	0.007	75.40%	0.017
Type of analysis										
Univariable	1	-	-	-	-	1	-	-	-	-
Multivariable	7	1.66(1.46,1.88)	0	24.40%	0.243	6	1.39(1.24,1.56)	0	54.00%	0.054
dNLR cut-off value										
<3	3	1.48(1.15,1.90)	0.002	0.00%	0.568	3	1.51(1.01,2.26)	0.043	71.10%	0.031
≥3	5	1.72(1.49,1.99)	0	37.60%	0.17	4	1.33(1.14,1.55)	0	21.00%	0.284

Publication bias

We conducted Begg's and Egger's linear regression test to assess publication bias. OS publication bias was not discovered in studies with dNLR ($Pr>|z|=0.902$ for Begg's test and $P>|t|=0.648$ for Egger's test); publication bias was also not detected for PFS ($Pr>|z|=0.764$ and $P>|t|=0.392$, respectively). The plots of Begg's test and Egger's test are shown in Figure 4.

Figure 4. Funnel plot for analysis of publication bias. (A) Funnel plot established using Begg's test for studies with OS; (B) funnel plot utilising Egger's test for studies with OS. (C) Funnel plot established utilising Begg's test for studies with PFS; (D) funnel plot utilising Egger's test for studies with PFS.

Discussion

This meta-analysis evaluated the results of 2,456 NSCLC patients in 8 studies. The results showed that high level dNLR was a significant predictor of worse OS (HR = 1.65, [95% CI (1.46~1.88)]; $P < 0.001$) and PFS (HR = 1.38, [95% CI (1.23~1.55)]; $P < 0.001$) of NSCLC patients treated with ICIs. Subgroup analyses of OS-related studies indicated similar results in stratifications by ethnicity, sample size, type of HR, and dNLR cut-off value. In PFS-related studies, subgroup analyses showed that there was no significant difference in the Asian sample group, but Asian sample subgroup only included 2 studies, which might weaken the credibility of the results of subgroup analysis. We conclude that pretreatment dNLR may be an important biomarker of the prognosis of NSCLC patients treated with ICIs.

Inflammation tends to lead to the development of cancer and stimulates all stages of tumourigenesis through multiple mechanisms.²⁹ Induction of inflammation can bring increased mutagenesis, leading to collection of mutations in normal tissue that can further cause tumour formation.^{30 31} Unlike in earlier stages of oncogenesis, cancer-related inflammation plays a crucial role in regulation of metastasis and leads to worse mortality.³² Additionally, the inflammation process has been suggested as a reason for

1
2
3
4 immune resistance in cancer patients. The cellular effectors of inflammation are
5 significant elements of the tumour microenvironment that break down adaptive immune
6 responses and impede responses to anti-tumour agents.³³ Moreover, a peripheral pro-
7 inflammatory condition has been linked to poor prognosis in patients with cancer¹¹.
8
9 Many routine blood indices including WBC, CRP, absolute neutrophil count, and
10 lactate dehydrogenase level have been evaluated as potential inflammatory biomarkers,
11 which are associated with worse survival in various types of cancer.³⁴⁻³⁶ Novel
12 biomarkers such as NLR, lymphocyte-monocyte ratio (LMR), and lymphocyte-platelet
13 ratio (PLR) have also been used to assess inflammatory status in several cancer types,
14 including NSCLCs.³⁷⁻³⁹ In particular, NLR is a well-studied prognostic predictor in
15 NSCLC patients, and some meta-analyses have confirmed the predictive value of NLR
16 in patients with NSCLC.^{40 41}

17
18 Recent studies indicated that dNLR is a novel serum marker of inflammatory in NSCLC
19 patients treated with ICIs.^{17 42} Although some studies have suggested relationships
20 between NLR and survival and therapeutic outcomes in NSCLC patients treated with
21 anti-PD-1 inhibitors,^{12 43 44} dNLR may be more strongly linked because it includes
22 monocytes and other granulocytes. Immature or poorly differentiated neutrophils can
23 be released in a pro-inflammatory environment, which increases neutrophil generation
24 rapidly. dNLR seems to reflect this negative inflammation more comprehensively. Our
25 study demonstrated that dNLR may be a valuable prognostic serum biomarker for
26 clinicians' decision making in NSCLC ICIs treatment. Future studies should pay more
27 attentions to the prognostic effect of dNLR on the NSCLC patients with ICIs. A larger
28 sample study is needed to verify our results.

29
30 In our study, most included studies have chosen a dNLR cut-off value of 3 to distinguish
31 the prognosis of NSCLC patients treated with ICIs, however, the selection and source
32 of dNLR cut-off values were rarely mentioned in original studies. We performed
33 subgroup analysis according to different dNLR cut-off levels, the results show that
34 significant HR of OS and PFS could be produced by all subgroups. It is also probably
35 necessary to use receiver operating characteristic (ROC) curves or other tools to
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 determine the optimal pretreatment dNLR cut-off value based on large sample data, so
5 that dNLR can be better applied to clinical practice. In addition, the included original
6 studies did not provide information that might affect dNLR, such as related diseases,
7 previous treatment, etc. These factors may lead to differences in the baseline
8 characteristics of the patients, which may influence the interpretation of our results. In
9 the future study, we will pay more attention to this aspect, and more comprehensive
10 original studies should be used to obtain more reliable results.

11
12
13
14
15
16
17 Several limitations of our meta-analysis require careful consideration. First, the
18 eligible studies were all retrospective, retrospective study is more prone to several bias
19 including selection, recall and measurement biases, so these retrospective biases may
20 influence the accuracy of results. Although recall bias was not explicit mentioned in the
21 original studies, the systematic error between the accuracy or integrity and the real
22 situation is often the result of the memory distortion or incomplete recall of the research
23 object when collecting the information. In addition, most of the included studies were
24 retrospective and single institution case series, and as mentioned above, the original
25 study did not provide more information such as other diseases and previous treatment
26 and so on, which may lead to selection bias. Second, although neither Begg's test nor
27 Egger's test showed publication bias in this study, the effectiveness of the two tests was
28 low when the number of meta-analyses was < 10 . In addition, our study mainly searched
29 English-language databases. Hence, publication bias should also be considered.

30
31
32
33
34
35
36
37
38
39
40
41
42 In conclusion, this meta-analysis revealed that elevated pretreatment dNLR may be a
43 negative prognostic index for NSCLC patients treated with ICIs. Future well-designed
44 and large-scale studies are needed to validate the result.

45 46 47 48 **Acknowledgements**

49
50 None.

51 52 **Author contributions**

53
54 ZL and SQ put forward the idea of research. The search strategy was developed and
55 conducted by TY, LH, and XY. LH and XY independently screened the titles and
56 abstracts of all included studies. Data extraction was performed by LH, XY, CL, and
57
58
59
60

1
2
3
4 GW. TY and LH conducted the meta-analysis. Manuscript was written by TY and CLC.
5

6 **Funding**

7 None.
8

9 **Compliance with ethical standards**

10 **Conflict of interest**

11 The authors declare that they have no competing interests.
12

13 **Ethical approval**

14 Not applicable.
15

16 **Patient consent for publication**

17 Not applicable.
18

19 **Data availability**

20 No additional data available.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71(3):209-49. doi: 10.3322/caac.21660 [published Online First: 2021/02/05]
2. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. *Mayo Clinic proceedings* 2019;94(8):1623-40. doi: 10.1016/j.mayocp.2019.01.013 [published Online First: 2019/08/06]
3. Ko EC, Raben D, Formenti SC. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. *Clin Cancer Res* 2018;24(23):5792-806. doi: 10.1158/1078-0432.Ccr-17-3620 [published Online First: 2018/06/28]
4. Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. *Ann Oncol* 2018;29(4):959-65. doi: 10.1093/annonc/mdy041 [published Online First: 2018/02/07]
5. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016;387(10027):1540-50. doi: 10.1016/S0140-6736(15)01281-7 [published Online First: 2015/12/30]
6. Lu S, Wang J, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). *Lung Cancer* 2021;152:7-14. doi: 10.1016/j.lungcan.2020.11.013 [published Online First:

- 1
2
3
4 2020/12/16]
- 5
6
7 7. Amrane K, Geier M, Corre R, et al. First-line pembrolizumab for non-small cell lung cancer
8
9 patients with PD-L1 \geq 50% in a multicenter real-life cohort: The PEMBREIZH study.
10
11 *Cancer Med* 2020;9(7):2309-16. doi: 10.1002/cam4.2806 [published Online First:
12
13 2020/02/06]
- 14
15
16
17 8. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III
18
19 Non-Small-Cell Lung Cancer. 2017;377(20):1919.
- 20
21
22 9. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after
23
24 Chemoradiotherapy in Stage III NSCLC. *N Engl J Med* 2018;379(24):2342-50. doi:
25
26 10.1056/NEJMoa1809697 [published Online First: 2018/10/04]
- 27
28
29
30 10. Bodor JN, Bumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-
31
32 small cell lung cancer (NSCLC). *Cancer* 2020;126(2):260-70. doi: 10.1002/cncr.32468
33
34 [published Online First: 2019/11/07]
- 35
36
37
38 11. Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index
39
40 With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small
41
42 Cell Lung Cancer. *JAMA oncology* 2018;4(3):351-57. doi:
43
44 10.1001/jamaoncol.2017.4771 [published Online First: 2018/01/13]
- 45
46
47
48 12. Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a
49
50 marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung
51
52 cancer. *Lung Cancer* 2017;106:1-7. doi: 10.1016/j.lungcan.2017.01.013
53
54 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25. [published Online First: 2017/03/14]
- 55
56
57
58 13. Pine JK, Morris E, Hutchins GG, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal
59
60

- 1
2
3
4 cancer: the relationship to patient survival, tumour biology and local lymphocytic
5
6 response to tumour. *Br J Cancer* 2015;113(2):204-11. doi: 10.1038/bjc.2015.87
7
8
9 [published Online First: 2015/07/01]
10
11
12 14. Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio
13
14 predicts survival in patients with cancer. *Br J Cancer* 2012;107(4):695-9. doi:
15
16 10.1038/bjc.2012.292 [published Online First: 2012/07/26]
17
18
19 15. Afzal MZ, Sarwar T, Shirai K. Prognostic Significance of Hematological Indices in Malignant
20
21 Melanoma Treated With Immune Checkpoint Inhibitors. *J Immunother* 2019;42(7):251-
22
23 64. doi: 10.1097/cji.0000000000000272 [published Online First: 2019/05/31]
24
25
26
27 16. Bruixola G, Caballero J, Papaccio F, et al. Prognostic Nutritional Index as an independent
28
29 prognostic factor in locoregionally advanced squamous cell head and neck cancer.
30
31 *ESMO open* 2018;3(6):e000425. doi: 10.1136/esmopen-2018-000425 [published
32
33 Online First: 2018/11/15]
34
35
36
37 17. Russo A, Franchina T, Ricciardi GRR, et al. Baseline neutrophilia, derived neutrophil-to-
38
39 lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small
40
41 cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. *Journal of cellular*
42
43 *physiology* 2018;233(10):6337-43. doi: 10.1002/jcp.26609
44
45
46
47
48 18. Su S, Liu L, Li C, et al. Prognostic role of pretreatment derived neutrophil to lymphocyte
49
50 ratio in urological cancers: A systematic review and meta-analysis. *International journal*
51
52 *of surgery (London, England)* 2019;72:146-53. doi: 10.1016/j.ijsu.2019.10.043
53
54
55
56 [published Online First: 2019/11/11]
57
58
59 19. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and
60


- 1
2
3
4 derived NLR are associated with poor prognosis in patients with breast cancer: A meta-
5
6 analysis. *Medicine* 2018;97(49):e13340. doi: 10.1097/md.00000000000013340
7
8 [published Online First: 2018/12/14]
9
10
11 20. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies
12
13 in Meta-Analyses. Symposium on Systematic Reviews: Beyond the Basics; 2014.
14
15
16
17 21. Takada K, Takamori S, Yoneshima Y, et al. Serum markers associated with treatment
18
19 response and survival in non-small cell lung cancer patients treated with anti-PD-1
20
21 therapy. *Lung Cancer* 2020;145:18-26. doi: 10.1016/j.lungcan.2020.04.034
22
23
24
25 22. Yuan S, Xia Y, Shen L, et al. Development of nomograms to predict therapeutic response
26
27 and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.
28
29 *Cancer Immunology, Immunotherapy* 2020 doi: 10.1007/s00262-020-02710-9
30
31
32
33 23. Prelaj A, Rebuzzi SE, Pizzutilo P, et al. EPSILoN: A Prognostic Score Using Clinical and
34
35 Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With
36
37 Immunotherapy. *Clinical lung cancer* 2020;21(4):365-77.e5. doi:
38
39 10.1016/j.clc.2019.11.017 [published Online First: 2020/04/05]
40
41
42
43 24. Seban RD, Assié JB, Giroux-Ieprieur E, et al. Association of the metabolic score using
44
45 baseline FDG-PET/CT and DNLR with immunotherapy outcomes in advanced NSCLC
46
47 patients treated with first - line pembrolizumab. *Cancers* 2020;12(8):1-14. doi:
48
49 10.3390/cancers12082234
50
51
52
53 25. Seban RD, Mezquita L, Berenbaum A, et al. Baseline metabolic tumor burden on FDG
54
55 PET/CT scans predicts outcome in advanced NSCLC patients treated with immune
56
57 checkpoint inhibitors. *European journal of nuclear medicine and molecular imaging*
58
59
60

- 2020;47(5):1147-57. doi: 10.1007/s00259-019-04615-x
26. Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *JAMA oncology* 2018;4(3):351-57. doi: 10.1001/jamaoncol.2017.4771
27. Kazandjian D, Gong Y, Keegan P, et al. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer. *JAMA oncology* 2019;5(10):1481-85. doi: 10.1001/jamaoncol.2019.1747
28. Altman DG, Bland JM. How to obtain the confidence interval from a P value. *BMJ* 2011;343:d2090. doi: 10.1136/bmj.d2090 [published Online First: 2011/08/10]
29. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. *Immunity* 2019;51(1):27-41. doi: 10.1016/j.immuni.2019.06.025 [published Online First: 2019/07/18]
30. Canli Ö, Nicolas AM, Gupta J, et al. Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis. *Cancer cell* 2017;32(6):869-83.e5. doi: 10.1016/j.ccell.2017.11.004 [published Online First: 2017/12/13]
31. Robles AI, Traverso G, Zhang M, et al. Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. *Gastroenterology* 2016;150(4):931-43. doi: 10.1053/j.gastro.2015.12.036 [published Online First: 2016/01/15]
32. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *Lancet* 2012;379(9826):1591-601. doi: 10.1016/s0140-6736(12)60209-8 [published Online

- 1
2
3
4 First: 2012/03/24]
5
6
7 33. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. *Nature*
8
9 2008;454(7203):436-44. doi: 10.1038/nature07205 [published Online First: 2008/07/25]
10
11
12 34. Soyano AE, Dholaria B, Marin-Acevedo JA, et al. Peripheral blood biomarkers correlate
13
14 with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1
15
16 antibodies. *J Immunother Cancer* 2018;6(1):129. doi: 10.1186/s40425-018-0447-2
17
18 [published Online First: 2018/11/25]
19
20
21
22 35. Wang H, Wang MS, Zhou YH, et al. Prognostic Values of LDH and CRP in Cervical Cancer.
23
24 *OncoTargets and therapy* 2020;13:1255-63. doi: 10.2147/ott.S235027 [published
25
26 Online First: 2020/02/28]
27
28
29
30 36. Yoon CI, Park S, Cha YJ, et al. Associations between absolute neutrophil count and
31
32 lymphocyte-predominant breast cancer. *Breast (Edinburgh, Scotland)* 2020;50:141-48.
33
34 doi: 10.1016/j.breast.2019.09.013 [published Online First: 2019/10/15]
35
36
37
38 37. Xiao X, Wang S, Long G. C-reactive protein is a significant predictor of improved survival
39
40 in patients with advanced non-small cell lung cancer. *Medicine* 2019;98(26):e16238.
41
42 doi: 10.1097/md.00000000000016238 [published Online First: 2019/07/03]
43
44
45
46 38. Machado D, Marques C, Dias M, et al. Inflammatory prognostic biomarkers in advanced
47
48 non-small cell lung cancer. *Pulmonology* 2019;25(3):181-83. doi:
49
50 10.1016/j.pulmoe.2019.02.007 [published Online First: 2019/04/03]
51
52
53
54 39. Cedrés S, Torrejon D, Martínez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator
55
56 of poor prognosis in stage IV non-small cell lung cancer. *Clin Transl Oncol*
57
58 2012;14(11):864-9. doi: 10.1007/s12094-012-0872-5 [published Online First:
59
60


1
2
3
4 2012/08/03]
5

- 6
7 40. Wang Z, Zhan P, Lv Y, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio
8
9 in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis.
10
11 *Translational lung cancer research* 2019;8(3):214-26. doi: 10.21037/tlcr.2019.06.10
12
13 [published Online First: 2019/08/02]
14
15
16
17 41. Benedict SD, Anne LJ, Dennis SJO, et al. Prognostic utility of baseline neutrophil-to-
18
19 lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-
20
21 analysis. 2018;Volume 11:955-65.
22
23
24
25 42. Blanc-Durand F, Auclin E, Planchard D, et al. Association of lung immune prognostic index
26
27 (LIPI) with survival of first line immune checkpoint inhibitors single agent or in
28
29 combination with chemotherapy in untreated advanced NSCLC patients. *Annals of*
30
31 *Oncology* 2019;30:xi5. doi: 10.1093/annonc/mdz447.015
32
33
34
35 43. Park W, Lopes G. Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker
36
37 in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer. *Clinical lung cancer*
38
39 2019;20(3):143-47. doi: 10.1016/j.clcc.2018.12.003 [published Online First: 2019/01/27]
40
41
42
43 44. Jiang T, Bai Y, Zhou F, et al. Clinical value of neutrophil-to-lymphocyte ratio in patients with
44
45 non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. *Lung Cancer*
46
47 2019;130:76-83. doi: 10.1016/j.lungcan.2019.02.009 [published Online First:
48
49 2019/03/20]
50
51
52
53
54
55
56
57
58
59
60



Flow chart of the eligible studies


181x245mm (150 x 150 DPI)



Forest plot of the association between pretreatment dNLR and OS

456x326mm (72 x 72 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Forest plot of the association between pretreatment dNLR and PFS

464x327mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Funnel plot for analysis of publication bias



PRISMA 2020 for Abstracts Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	6



PRISMA 2020 for Abstracts Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7-8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	13
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14-15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	15

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.



PRISMA 2020 for Abstracts Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	Yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Yes
Synthesis of results	6	Specify the methods used to present and synthesise results.	Yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	No
Registration	12	Provide the register name and registration number.	Yes

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

Supplementary Table 1 Search strategies for PubMed, Embase, Cochrane Library and Web of science

Database	Keywords
PubMed	
#1	"Carcinoma, Non-Small-Cell Lung"[Mesh]
#2	(Carcinoma, Non Small Cell Lung[Title/Abstract]) OR (Carcinomas, Non-Small-Cell Lung[Title/Abstract]) OR (Lung Carcinoma, Non-Small-Cell[Title/Abstract]) OR (Lung Carcinomas, Non-Small-Cell[Title/Abstract]) OR (Non-Small-Cell Lung Carcinomas[Title/Abstract]) OR (Nonsmall Cell Lung Cancer[Title/Abstract]) OR (Non-Small-Cell Lung Carcinoma[Title/Abstract]) OR (Non Small Cell Lung Carcinoma[Title/Abstract]) OR (Carcinoma, Non-Small Cell Lung[Title/Abstract]) OR (Non-Small Cell Lung Cancer[Title/Abstract])
#3	#1 OR #2
#4	(checkpoint*[Title/Abstract]) OR ("checkpoint inhibitor"[Title/Abstract]) OR (CTLA-4[Title/Abstract]) OR (PD-1[Title/Abstract]) OR (PD-L1[Title/Abstract]) OR (ipilimumab[Title/Abstract]) OR (atezolizumab[Title/Abstract]) OR (durvalumab[Title/Abstract]) OR (pembrolizumab[Title/Abstract]) OR (nivolumab[Title/Abstract]) OR (avelumab[Title/Abstract]) OR (tremelimumab[Title/Abstract])
#5	(derived neutrophil-lymphocyte ratio[Title/Abstract]) OR (dNLR[Title/Abstract]) OR (derived neutrophil lymphocyte ratio[Title/Abstract]) OR (derived neutrophil to lymphocyte ratio[Title/Abstract])
#6	#3 AND #4 AND #5
Embase	
#1	'non small cell lung cancer'/exp
#2	'carcinoma, non small cell lung':ab,ti OR 'carcinomas, non-small-cell lung':ab,ti OR 'lung carcinoma, non-small-cell':ab,ti OR 'lung carcinomas, non-small-cell':ab,ti OR 'non-small-cell lung carcinomas ':ab,ti OR 'non small cell lung cancer':ab,ti OR 'non-small-cell lung carcinoma':ab,ti OR 'non small cell lung carcinoma ':ab,ti OR 'carcinoma, non-small cell lung':ab,ti OR 'non-small cell lung cancer':ab,ti
#3	#1 OR #2
#4	'checkpoint*':ab,ti OR 'checkpoint inhibitor':ab,ti OR 'ctla-4':ab,ti OR 'pd-1':ab,ti OR 'pd-11':ab,ti OR 'ipilimumab':ab,ti OR 'atezolizumab':ab,ti OR 'durvalumab':ab,ti OR 'pembrolizumab':ab,ti OR 'nivolumab':ab,ti OR 'avelumab':ab,ti OR 'tremelimumab':ab,ti
#5	'derived neutrophil-lymphocyte ratio':ab,ti OR 'dnlr':ab,ti OR 'derived neutrophil lymphocyte ratio':ab,ti OR 'derived neutrophil to lymphocyte ratio':ab,ti
#6	#3 AND #4 AND #5
Cochrane Library	
#1	MeSH: Carcinoma, Non-Small-Cell Lung

#2	(Carcinoma, Non Small Cell Lung):ti,ab,kw OR (Carcinomas, Non-Small-Cell Lung):ti,ab,kw OR (Lung Carcinoma, Non-Small-Cell):ti,ab,kw OR (Lung Carcinomas, Non-Small-Cell):ti,ab,kw OR (Non-Small-Cell Lung Carcinomas):ti,ab,kw OR (Non small Cell Lung Cancer):ti,ab,kw OR (Non-Small-Cell Lung Carcinoma):ti,ab,kw OR (Non Small Cell Lung Carcinoma):ti,ab,kw OR (Carcinoma, Non-Small Cell Lung):ti,ab,kw OR (Non-Small Cell Lung Cancer):ti,ab,kw
#3	#1 OR #2
#4	(checkpoint*):ti,ab,kw OR (checkpoint inhibitor):ti,ab,kw OR (CTLA-4):ti,ab,kw OR (PD-1):ti,ab,kw OR (PD-L1):ti,ab,kw OR (ipilimumab):ti,ab,kw OR (atezolizumab):ti,ab,kw OR (durvalumab):ti,ab,kw OR (pembrolizumab):ti,ab,kw OR (nivolumab):ti,ab,kw OR (avelumab):ti,ab,kw OR (tremelimumab):ti,ab,kw
#5	(derived neutrophil-lymphocyte ratio):ti,ab,kw OR (dNLR):ti,ab,kw OR (derived neutrophil lymphocyte ratio):ti,ab,kw OR (derived neutrophil to lymphocyte ratio):ti,ab,kw
#6	#3 AND #4 AND #5
Web of science	
#1	TS=(Carcinoma, Non-Small-Cell Lung OR Carcinoma, Non Small Cell Lung OR Carcinomas, Non-Small-Cell Lung OR Lung Carcinoma, Non-Small-Cell OR Lung Carcinomas, Non-Small-Cell OR Non-Small-Cell Lung Carcinomas OR Non small Cell Lung Cancer OR Non-Small-Cell Lung Carcinoma OR Non Small Cell Lung Carcinoma OR Carcinoma, Non-Small Cell Lung OR Non-Small Cell Lung Cancer)
#2	TS=(checkpoint* OR checkpoint inhibitor OR CTLA-4 OR PD-1 OR PD-L1 OR ipilimumab OR atezolizumab OR durvalumab OR pembrolizumab OR nivolumab OR avelumab OR tremelimumab)
#3	TS=(derived neutrophil-lymphocyte ratio OR Dnlr OR derived neutrophil lymphocyte ratio OR derived neutrophil to lymphocyte ratio)
#4	#1 AND #2 AND #3